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Abstract 
Ischemia reperfusion injury (IRI) occurs during transplantation and causes apoptosis and 
inflammation. The purpose of this research was to determine the effect of caspase-3, 
complement 3, and RelB gene silencing in the reduction of IRI using an in vitro model. 
LLC-PK1 cells were used along with antimycin A for the in vitro IRI model. Prior to 
exposure to antimycin A, cells were transfected with caspase-3, C3, and RelB small 
interfering RNA (siRNA) alone or in combination and then analyzed. 
The relative risk reduction of apoptosis in antimycin A treated cells with caspase-3 siRNA 
was 46.6% (p=0.019), RelB siRNA 42.8% (p=0.038), and complement 3 siRNA 13.9% 
(p=0.968). Combinations caspase-3 and RelB siRNAs showed significant changes, but were 
similar to transfection with caspase-3 and RelB alone. 
Caspase-3 and RelB siRNA are effective at reducing apoptosis in an in vitro model of IRI 
and will be used in future large animal studies. 
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RNA Interference, siRNA, Ischemia Reperfusion Injury, Transplantation, Apoptosis, 
Complement Pathway, RelB, Hypoxia. 
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Chapter 1  
1 Introduction 
1.1 Overview 
End stage renal disease (ESRD) affects many patients in Canada and the number 
continues to increase. ESRD is generally defined as chronic kidney disease that is being 
treated by dialysis or renal transplantation (1). In 2012, there were 41,252 people living 
with ESRD, and 5,431 patients were newly diagnosed with ESRD. This is nearly two fold 
that which were diagnosed in 1993 (2). In Canada and the United States, the most 
common causes of ESRD include diabetes, hypertension, glomerulonephritis, and cystic 
kidney disease (2, 3). Other less common causes include drug induced ESRD and 
pyelonephritis (2). Patients with ESRD often have significant co-morbidities including 
coronary artery disease, hypertension, and diabetes which leads to increased morbidity 
and mortality as well as increased health care costs (1). ESRD leads to a significant 
amount of health care spending, and in the United States in 2011, ESRD accounted for 
$34.3 billion in Medicare costs (3). 
Renal replacement therapy (RRT) is the mainstay of treatment for ESRD. ESRD may be 
treated using different types of RRT which include hemodialysis, peritoneal dialysis, and 
renal transplantation. The type of RRT that is initiated will depend on many factors such 
as age, co-morbidities, availability of the various options, and supports at home. 
Hemodialysis requires vascular access and this can be achieved in the form of primary 
arteriovenous (AV) fistulas, synthetic AV fistulas, and double lumen catheters (1). 
Hemodialysis can be performed at home or in an outpatient setting. Peritoneal dialysis 
requires an intra-abdominal peritoneal dialysis catheter and is performed at home by 
patients. For patients who are candidates, dialysis often provides a bridge to renal 
transplantation. Renal transplantation provides the best treatment for ESRD. However, 
not all patients are candidates for transplantation and significantly, there are a limited 
number of donor organs available.  
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1.2 Renal Transplantation 
1.2.1 Overview 
The first successful renal transplant was performed in 1954 and involved two identical 
twins (4). Since that time, the field of transplantation has expanded rapidly and many 
important milestones have been reached. In 1961, azathioprine was first used to prevent 
rejection in an unrelated kidney transplant patient (5). This patient and the next ultimately 
died shortly after transplantation due to the toxicity of azathioprine. However, the third 
patient was treated successfully and azathioprine eventually became well established in 
the prevention of rejection (5). Prednisone, tissue typing, and the development of 
antilymphocyte globulin also improved outcomes through the 1970s (5). Unfortunately, 
large doses of prednisone leading to steroid dependence contributed to increased 
morbidity and mortality. The introduction of cyclosporine in 1979, and then tacrolimus in 
1989, allowed for significant improvements in the prevention of rejection (6). 
Refinements in the timing of the administration of anti-rejection medications have lead to 
an improvement in the morbidity associated with immunosuppresion. Since 2001, pre-
transplant treatment with an antilymphoid antibody followed by tacrolimus post-
transplant has been shown to be effective and reduces the complications associated with 
long-term immunosuppresion (6). 
Renal transplantation continues to be the best form of RRT in the treatment of ESRD. 
There have been numerous studies which demonstrate a survival benefit in patients who 
have undergone renal transplantation compared to those who continue with dialysis for 
RRT (7-10). Renal transplantation is also more cost effective in the long-term, but has 
higher initial costs. The per person per year costs for Medicare in the United States in 
2011 were $87,945 for hemodialysis, $71,630 for peritoneal dialysis, and $32,922 for 
renal transplantation (3). Renal transplantation is also more convenient for patients as 
they do not need to undergo dialysis multiple times per week. Although there are 
significant benefits with renal transplantation, there continues to be a worldwide shortage 
of available organs for transplantation. In Canada in 2012, there were 1054 renal 
transplants performed, and 2469 patients on the waiting list (2). Organs may be retrieved 
from living donors or deceased donors. In the past, deceased donors were those who were 
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determined to have a neurologically determined death (NDD). In order to expand the 
amount of available organs, efforts have been made in recent years to procure organs 
from patients who have undergone a cardiac arrest. This has been termed donation after 
cardiac death (DCD). There has also been a move to increase the number of living and 
deceased donors by accepting organs from those who do not meet the usual criteria. This 
has been termed expanded criteria donor (ECD). These new categories have also created 
the need to define a standard criteria donor (SCD) which is a donor that has undergone 
brain death and does not meet the criteria for an ECD (11). 
1.2.2 DCD and ECD in Transplantation 
DCD donors are deceased donors in whom cardiac arrest or cessation of cardiac function 
occurs prior to procurement of organs (11-13). This results in a situation in which the 
organs which are procured are either not perfused or under perfused for a period of time 
and remain in the donor’s body until death can be confirmed and the patient taken to the 
operating room (OR). This is commonly referred to as the warm ischemic time (WIT). 
The functional WIT more specifically refers to the period of time during which the 
donor’s systolic blood pressure drops below 50mmHg or the arterial oxygen saturation 
drops below 70 percent, and lasts until the organs are perfused with preservation solution. 
Once procured and placed on ice, this signifies the start of the cold ischemic time (CIT) 
(12). The WIT in organs from DCD donors causes an additional insult to the organs that 
is not seen in organs from NDD donors as the WIT is very short and lasts for only a few 
minutes. This leads to fewer organs being accepted for transplantation from DCD donors 
and a higher rate of delayed graft function (DGF) in transplanted kidneys. The discard 
rate for organs which have been procured but are not transplanted is around 20 percent 
for DCD donors (14). DGF is usually defined as the need for dialysis within the first 
week of transplantation and this leads to increased costs and morbidity (15). The rate of 
DGF in kidneys from DCD donors is twice that of kidneys from SCD donors, however, 
although the rate of DGF is significantly higher, the five-year overall graft survival rate is 
similar between the two groups (14). The use of DCD donors in Canada continues to 
increase while the NDD donor rate has remained relatively stable over the last ten years 
(Figure 1) (2). 
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Figure 1 - Kidneys transplanted from DCD and NDD donors in Canada from 2003 
to 2012 (2). 
There are five different categories of DCD donors according to the modified Maastricht 
classification (12, 13). These include the following: 
1. Dead on arrival  
2. Unsuccessful resuscitation 
3. Cardiac arrest after withdrawal of life support in patients who are not brain dead 
4. Cardiac arrest after brain death 
5. Unexpected cardiac arrest in an intensive care unit (ICU) patient 
The classes can also be more generally categorized into controlled and uncontrolled DCD 
donors (11). Controlled donors come from classes 3 and 4, and uncontrolled donors from 
classes 1, 2, and 5. A controlled DCD donor is a patient whose family has provided 
consent for organ donation, but as in class 3, is not brain dead, or in class 4, an 
unexpected cardiac arrest occurs in an already identified donor who is brain dead. Class 4 
donors are very rare and most of the controlled DCD donors come from class 3. In this 
case, life support is withdrawn after the transplant team is ready, and the donor monitored 
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until there is no mechanical cardiac function or signs of life. This can be determined by 
an arterial catheter, loss of pulsatile blood flow on Doppler ultrasound, or loss of blood 
flow on echocardiography (16). Asystole on a cardiac monitor is also sufficient for this 
determination as there can be no mechanical cardiac function if there is no electrical 
activity. After this, the donor is further monitored for a set period of time to ensure that 
there is no return of cardiac function or auto-resuscitation. This period of time varies 
from hospital to hospital and is the focus of ongoing debate as the removal of organs 
cannot contribute to the death of the donor (12, 16). This time must not be prolonged so 
as not to increase the WIT, however. A time of 5 minutes is generally accepted as an 
appropriate amount of time in order to ensure that the cessation of cardiac function is 
permanent, as the longest reported time of auto-resuscitation after asystole is 65 seconds 
(16, 17). The determination of death must then be done by someone who is not associated 
with the transplant team to avoid any conflict of interest. After the determination of 
death, the donor is transferred to the OR, if they are not there already, for procurement of 
the organs. Withdrawal of life support can occur either in the OR or in the ICU. The OR 
allows for a decreased WIT, however the ICU allows for the family to remain by the 
bedside until the donor is deceased and, in general, is a better place for withdrawal of life 
support.  
Uncontrolled DCD donors are significantly different from controlled DCD donors in that 
warm ischemia will already be established before the decision is made to consider 
donation. This type of donation is practiced in some countries (e.g. Spain) and usually 
only makes use of the kidneys (12). After the determination of death in potential 
uncontrolled DCD donors, the common femoral artery is canulated with a double-
balloon, triple lumen catheter with the lower balloon lodged at the aortic bifurcation and 
the upper balloon above the renal arteries. The kidneys are then perfused with cold 
preservation solution. A catheter is also inserted into the femoral vein to allow outflow of 
the preservation solution. At this point consent is obtained from family members, if not 
already done, and the donor transferred for procurement of the kidneys (18). 
Alternatively, an external cardiac compression and ventilation machine is used until 
consent can be obtained by family and then the common femoral artery is canulated (19). 
Strict criteria are needed to ensure that the kidneys obtained from these donors are of a 
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high enough quality for transplantation. In a retrospective review from Belgium, Dupriez 
et al. found that over 14 years, 39 procedures were initiated on potential uncontrolled 
DCD donors. Of the 78 kidneys available, only 40 were procured, and of these, only 25 
were transplanted. Overall, there was a 32 percent kidney conversion rate (percentage of 
kidneys transplanted from donors who had the procedure initiated). They also found that 
DGF occurred in 54 percent of kidneys and the one-year graft survival rate was 86 
percent (18). Uncontrolled DCD occurs in a number of countries, and in some is the only 
form of DCD. Protocols vary between countries for both controlled and uncontrolled 
DCD including determination of death, preservation of organs while awaiting family 
consent, and an opt-in versus opt-out system of consent for organ donation (20). This 
leads to many ethical considerations for both types of DCD as it is important to ensure 
that procurement of the organs is not the cause for death. 
ECD donors present another challenge in transplantation. An ECD donor is defined as a 
donor who is over the age of 60, or who is between the ages of 50-59 with two of the 
following: hypertension, cerebrovascular accident as the cause of death, or a creatinine 
above 120umol/L. The use of ECD donors is necessary to increase the amount of organs 
available for transplantation, however these organs are of a lower quality due to the donor 
characteristics. ECD donors may either be living or deceased donors and the overall rate 
of DGF is approximately 30% which is below the rate seen in DCD donors (14). The five 
year graft survival rate has been shown to be 72.1% and 86.9% for ECD and SCD 
deceased donor kidneys, respectively, in a recent study by Papachristou et al. (21). They 
also found that the overall survival rates were similar at 5 years between the groups and 
slightly favoured the SCD group at 10 years. Additionally, older patients were more 
likely to receive kidneys from ECD donors and this may have contributed to the 
decreased overall survival at 10 years. 
Although many advances have been made in transplantation, the need to develop ways to 
protect the graft during procurement, transport, and implantation is still in need of novel 
methods. This is especially important in DCD and ECD organs which inherently are of a 
lower quality than those obtained from living or NDD donors who meet the criteria for a 
SCD. There is a significant amount of injury that can occur during this time and it is a 
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type of ischemia reperfusion injury (IRI). IRI occurs when there is a partial or complete 
cessation of blood flow to a tissue or organ followed by a reperfusion phase. Therapies 
that target IRI may have a significant benefit in increasing the quality and survival or 
grafts, and demand further investigation and research. 
1.3 Ischemia Reperfusion Injury 
1.3.1 Overview 
IRI occurs in a number of different clinical settings including myocardial infarction, 
shock, acute limb ischemia, compartment syndrome, and transplantation (22). IRI occurs 
as a result of many complex molecular pathways and can be separated broadly into the 
ischemic and reperfusion phases. The duration of the ischemic phase is variable and 
related to the amount of injury observed. The amount of injury observed is also 
dependent on the type of organ or tissue affected with the brain and heart being most 
susceptible with irreversible damage seen in less than 20 minutes and at 20 minutes, 
respectively. The kidney can withstand normothermic ischemia for up to 30 minutes (23).  
Therefore, in order to decrease the amount of IRI in renal transplantation, kidneys are 
stored at 4
0
C after being flushed with a preservation solution to decrease the metabolic 
activity of the cells by 12 to 13 times (24). This allows for the identification of a recipient 
as well as transportation of the graft which can take many hours. These hypothermic 
conditions, however, have been shown to detrimental in experiments that have exposed 
renal tubular rat cells to hypothermia and subsequent rewarming without ischemia (25). 
Cell changes were seen which were similar to acute tubular necrosis in renal failure. A 
balance must therefore be achieved between protecting the grafts from IRI with 
hypothermic conditions and preventing cold-induced injury. IRI is a complex process and 
requires an understanding of the molecular and cellular changes which occur in order to 
identify the potential therapies. 
1.3.2 Molecular Events in IRI 
As has been stated, IRI can be broadly separated into the ischemic and reperfusion 
phases. During these ischemic phases, blood flow to the affected organ or tissue is 
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interrupted, either completely (as in transplantation) or incompletely, and leads to 
decreased oxygen delivery. This causes a switch from aerobic to anaerobic metabolism, 
reduced ATP production, a decrease in the pH due to lactic acidosis, and a buildup of 
toxic metabolites which cannot be cleared (22, 26, 27). Additionally, there is a buildup of 
sodium ions as the Na
+
/K
+
 ATPase is inhibited by the low pH and ATP levels and the 
Na
+
/H
+
 antiporter attempts to expel H
+
 ions to increase the pH. The increased 
concentration of sodium in the cell also causes an influx of water which causes the cells 
to become edematous. Arrest of glycolysis with a buildup of the intermediates further 
increases the osmolarity in the cells and edema (22, 28).  
A rise in the concentration of sodium in the cell also leads to a reversal of the Na
+
/Ca
2+
 
antiporter, and, along with a reduced uptake into the endoplasmic reticulum, there is a 
significant increase in calcium ions in the cell (22, 23, 28). High concentrations of 
calcium within the mitochondria lead to mitochondrial permeability transition pore 
(mPTP) opening and the release of cytochrome c. Cytochrome c is important in the 
initiation of apoptosis. mPTP opening does not happen immediately during the ischemic 
phase due to the acidotic environment and will occur during the reperfusion phase when 
the pH returns to a more physiologic level (22, 23). The increased calcium concentration 
will also lead to priming of caspases, phospholipases, and calcium dependent calpains 
which will also be activated when the pH is corrected (28). Calpains and caspases are 
proteases that are important in cell injury and death, and calpain inhibition has been 
shown to reduce the effects of IRI in an in vivo setting using rats (29). Caspase activation 
leads to apoptosis and will be expanded on in section 1.3.3: Cell Death in IRI.  
Additionally, increased cytosolic calcium causes activation of Ca
2+
/calmodulin-
dependent protein kinases (CaMKs). There are a number of different types of CaMKs, 
and some lead to cell death and adverse outcomes following IRI, while some have been 
shown to have a protective effect by inducing autophagy and decreased organ injury (30, 
31). Taken together, all of these changes set the ischemic cells up for an additional and 
more severe injury seen when the organ or tissue is reperfused and oxygen is delivered to 
the cells. 
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Reperfusion occurs in transplantation when the graft is once again perfused with blood 
from the recipient. This is obviously necessary for the function of the graft, but in itself, 
this event sets off an additional round of cellular injury that builds on the cellular 
processes during the ischemic phase. Two important events that take place during this 
time include the return of oxygen to the cell and the return to a physiologic pH. As the 
extracellular pH rises, the cells rapidly expel H
+ 
ions via the Na
+
/H
+
 antiporter. This 
further increases the sodium concentration in the cell and once again reverses the 
Na
+
/Ca
2+
 antiporter, increasing the calcium concentration in the cell (22). This further 
exacerbates the effects of calcium overload which occur during ischemia including mPTP 
opening and protease activation. Reperfusion also allows for the production of reactive 
oxygen species (ROS) which cause a significant amount of injury to the organ or tissue. 
ROS are generated during the ischemic and reperfusion phases, but mostly occur during 
the reperfusion phase. The principle ROS produced is superoxide (O2
-∙), as was shown in 
research that used superoxide dismutase (SOD) to effectively treat IRI, and is formed by 
the electron transport chain and by a number of different enzymes including cytochrome 
P450 oxidases, NADPH oxidase, nitric oxide synthase and xanthine oxidase (23, 32).  
In the mitochondria, the electron transport chain involves a number of redox reactions 
which lead to the reduction of molecular oxygen to water and drives the production of 
ATP. Normally, most of the oxygen is completely reduced, however, there is a baseline 
leak of superoxide that accounts for about 1-2% of the molecular oxygen used. This 
superoxide is rapidly scavenged by SOD and cytochrome c and does not cause much 
damage (23, 32). In IRI, the mitochondria accounts for a significant amount of ROS via 
increased production as well as a decreased capability to scavenge the ROS which are 
produced (23). 
Xanthine oxidase has been known for some time to be an important source of ROS and 
produces superoxide and hydrogen peroxide from molecular oxygen, water, and 
hypoxanthine (33, 34). Superoxide produced by xanthine oxidase and other enzymes may 
interact with iron-sulphide containing enzymes and inactivate them, but it is usually 
rapidly converted by SOD into molecular oxygen and hydrogen peroxide and is not 
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thought to contribute very much to the overall injury. However, superoxide may also be 
converted to the more reactive hydroperoxyl radical or react with nitric oxide (NO) to 
form peroxynitrous acid (ONOOH). Hydrogen peroxide can also generate the hydroxyl 
free radical (OH∙) (23, 32). These free radicals may then go on to create oxidative cellular 
stress. This occurs through the oxidation of macromolecules and the entire process can be 
separated into the initiation, propagation, and termination steps (32). The initiation step 
involves creation of the free radical as mentioned above. The propagation step in cells 
involves the production of alkyl radicals from alkene groups followed by the addition of 
molecular oxygen to the alkyl radical to produce a peroxyl radical. The termination step 
involves a single electron redox reaction to a non radical. This step often produces a 
molecule which is unstable within the cell structure. For example, lipid peroxidation can 
affect the cell and mitochondrial membrane, DNA oxidation can create mutations within 
the genetic code, and amino acid oxidation or nitration can damage proteins and affect 
their function (32). Whether or not a cell dies depends on the extent of damage caused by 
the ROS and whether the cell is able to repair the affected macromolecules.  
This release of ROS is followed by the migration of leukocytes to the affected tissue or 
organ which in turn produce a large amount of ROS and proteases, leading to further 
injury and cell death (34). The significant changes in cellular ion concentrations and the 
massive release of ROS in IRI leads to inflammation and activation of the immune 
system and can induce cellular death in a number of different ways. 
1.3.3 Cell Death in IRI 
Cellular death in IRI occurs through apoptosis, autophagy, necrosis, and a recently 
discovered process known as necroptosis or regulated necrosis (23). Apoptosis is the term 
given to programmed cell death and leads to cell shrinkage, blebbing, nuclear 
fragmentation, degradation of DNA, exteriorization of phosphatidylserine, and 
phagocytosis of the cell fragments in the absence of inflammation (35, 36). This process 
is essential to the normal growth and development of all organisms and all cells contain 
the enzymes which are required for the initiation and progression of apoptosis. These 
enzymes are the caspases and can be activated through intrinsic or extrinsic pathways 
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when the cell is exposed to conditions which necessitate its death in a programmed, non-
inflammatory fashion (35).  
The intrinsic pathway can by activated by different types of cellular stress including 
DNA damage, oxidative stress, hypoxia, UV radiation, toxic compounds, and reduced 
growth factors (23, 36). This causes the integration of the pro-apoptotic proteins in the 
Bcl-2 protein superfamily into the outer mitochondrial membrane leading to the release 
of cytochrome c and other apoposis initiating proteins. Following its release into the 
cytosol, cytochrome c binds to apoptotic protein activating factor-1 (Apaf-1), forming an 
apoptosome which activates caspase-9. Caspase-9 then activates caspase-3 which leads to 
apoptosis through the degradation of many cellular proteins (23, 35, 36). Other proteins 
released from the mitochondria include endonuclease G (endoG) which is responsible for 
DNA fragmentation, as well as Smac/DIABLO and Omi-HtrA2 which bind and cleave 
inhibitors of apoptotic proteins (IAPs). IAPs are required for the inhibition of caspases 
(23, 35). The extrinsic pathway in apoptosis is activated by the binding of ligands to 
death receptors. These ligands include TNF superfamily proteins. Important death 
receptors include Fas, TNFα, and TRAIL which undergo trimerization when activated. 
Activation leads to the recruitment of the death domain proteins FADD and TRADD 
which activate caspase-8. Activated caspase-8 can then activate caspase-3, caspase-6, and 
caspase-7 leading to apoptosis (36). Apoptosis is an important form of cell death that 
occurs in IRI through both the intrinsic and extrinsic pathways.  
Another important form of cell death in IRI is autophagy which does have some overlap 
with apoptosis. Autophagic death involves the development of autophagic vacuoles or 
autophagosomes and does not involve inflammation, DNA degradation, or caspase 
activation (35, 36). Autophagosomes engulf damaged organelles or protein complexes 
and then fuse with lysosomes which contain enzymes that are able to degrade these 
structures. Autophagy is a normal pro-survival cellular process that leads to the turnover 
of macromolecules and can help during episodes of cellular stress such as infection, by 
providing amino acids and fatty acids. However, in times of severe stress, such as in IRI, 
autophagy can actually lead to cell death through ongoing degradation of cellular 
components (23). Many of the proteins involved in signaling in autophagy are also 
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involved in apoptosis, especially the Bcl-2 superfamily, and as such, there is significant 
overlap between the two processes (36). Both of these forms of cell death do not produce 
an inflammatory reaction as is seen in necrosis. 
Necrosis occurs in IRI as well and involves cell and organelle swelling, mitochondrial 
dysfunction, and eventual rupture of the plasma membrane and spilling of intracellular 
contents (23). This involves an inflammatory response as mast cells are attracted to the 
necrotic cells. Originally, this was thought to be an accidental type of cell death without 
cellular regulation and involving cell death that did not appear to be autophagic or 
apoptotic (35). Recently, however, the emerging concept of regulated necrosis has been 
developed in which the cell death is genetically controlled (23, 37). There are different 
forms of regulated necrosis such as necroptosis, ETosis, ferroptosis, NETosis, 
parthanatos, pyronecrosis, and pyroptosis. Necroptosis is the most studied and best 
understood currently. The receptor interacting protein kinase 1 (RIPK1) was first shown 
to be important in programmed cell death that was caspase independent and produced a 
necrotic morphology by Holler et al. (38). This represented an important discovery that 
lead to many further advancements in research into regulated necrosis. RIPK3 was 
subsequently identified and these two kinases have been shown to be essential in 
regulated necrosis. Interestingly, RIPK1 and RIPK3 signaling can lead to apoptosis as 
well, but when caspase-8 is inhibited, they activate mixed lineage kinase domain like 
(MLKL) leading to regulated necrosis. RIPK1 can also induce up-regulation of the non 
canonical NF-κβ pathway and increased cell death (23, 37). Regulated necrosis has been 
shown to be an important form of cell death in IRI, and is thought to be possibly more 
prevalent than apoptosis (39, 40). This was shown in a renal IRI model using two 
separate inhibitors. The first was necrostatin-1 which inhibits RIPK1, and the second was 
zVAD, an inhibitor of the caspases. It was shown that necrostatin-1 reduced organ 
damage, while zVAD did not produce similar results (39).  
Cells exposed to IRI can die through any of the mechanism described above and much 
research has focused on the inhibition of one or more of these mechanisms. It has been 
difficult to determine which mechanism predominates and is responsible for the most cell 
death. This is likely due to the fact that there are many different cellular pathways 
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controlling these processes and a lot of redundancy to ensure that cells which can no 
longer be salvaged are degraded. As a result of the significant injury caused by IRI and 
the reduced function of the graft following transplantation, it would be extremely 
beneficial to target one or more of the mechanisms to protect the cells and prevent both 
programmed and accidental cell death. Targeting the cells of the effected tissue or organ 
may not be enough however, as there is significant involvement of both the innate and 
adaptive immune systems in IRI. 
1.3.4 Innate Immunity in IRI 
Immune responses have been well studied in the context of graft rejection and effective 
therapies to deal with this have been developed which has lead to many advancements in 
transplantation. The innate and adaptive immune systems also respond to the injury 
caused by IRI, can lead to further cell death and damage and may be an important area to 
target in the prevention and treatment of IRI. Multiple pathways have been shown to be 
involved in the initiation and propogation of IRI. 
The innate immune system acts as a first line of defense against invading pathogens as 
well as tissue injury caused by conditions such as hypoxia. This is possible through the 
recognition of danger-associated molecular patterns (DAMPs) and pathogen-associated 
molecular patterns (PAMPs) by pattern recognition receptors (PRRs). DAMPs are 
produced during IRI and include high mobility group box-1 (HMGB-1), heparin sulphate, 
ROS, and heat shock proteins (41). Toll-like receptors (TLRs) are one class of PRR 
present on innate immune cells and TLR signaling is known to be activated in IRI. For 
example, TLR-4 is upregulated in renal IRI and leads to increased injury (42, 43). TLR 
signaling can occur through MyD88 dependent and independent pathways and leads to 
the activation of Nf-κβ. NF-κβ is an important transcription factor controlling cell 
survival, apoptosis, inflammation, and cell proliferation and can activate pro-survival or 
apoptotic processes depending on the situation and degree of cellular injury (44). NF-κβ 
is important in the upregulation of inflammatory cytokines and the innate and adaptive 
immune response following injury or infection. NF-κβ can lead to both the upregulation 
and downregulation of inhibitors of apoptosis, such as those in the Bcl-2 family. It may 
also upregulate pro-apoptotic genes, such as Bax and PUMA. It is very important in the 
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inflammatory response following IRI and subsequent cellular damage and death. NF-κβ 
factors contain Rel homology domains such as RelA, RelB, and c-Rel which are 
responsible for DNA binding. Different NF-κβ pathways exist including the canonical, 
non-canonical, and atypical pathways. RelB is part of the non-canonical pathway and its 
activation has been linked to apoptosis (45). Silencing of RelB with RelB siRNA in a 
mouse model of renal IRI showed a significant benefit in terms of renal function, 
histology, and overall survival (46). NF-κβ signaling is complex and has significant 
cross-talk with other cellular signaling pathways as well creating a potential for increased 
cell death or survival (44). Targeting the NF-κβ pathway may be challenging given its 
complexity and involvement in the regulation of many different genes, but may also offer 
some benefit in reducing apoptosis and the immune response early in the process of IRI. 
The complement system is also an important part of innate immunity and is activated in 
IRI. The complement system contains three pathways which converge with the activation 
of complement 3 (C3) which subsequently leads to formation of the membrane attack 
complex (MAC) which is composed of C5b-C9. The MAC is responsible for inducing 
direct cell lysis and the C3a and C5a fragments, known as anaphylatoxins, act as 
powerful mediators of inflammation. The complement pathways include the classical, 
alternative, and lectin pathways. The classical pathway is activated by the binding of 
antigens to immunoglobulins (IgG, IgM) or C-reactive protein (CRP), which then bind 
complement 1q (C1q). This activates C1s and C1r which cleave C4 and lead to the 
formation of C4b and C2b (from C2). This constitutes the C3 convertase which cleaves 
C3 into C3a and C3b and leads to activation of the rest of the complement cascade. The 
alternative pathway begins with the spontaneous hydrolysis of C3 into C3b and C3a. C3b 
is able to bind directly to the surface of pathogens and activate the complement cascade 
leading to the MAC. The lectin pathway involves mannose binding lectin (MBL) which 
binds to carbohydrate moieties on bacterial cell membranes. When activated, MBL, in 
association with the MBL-associated proteins (MASPs), cleaves C4 and activates the 
complement cascade (47). Although initially thought to only occur in the presence of 
infection, all of these pathways have been found to be involved in sterile inflammation 
such as IRI due to the release of  DAMPs (48, 49).  
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Complement activation is known to induce significant damage following transplantation 
from formation of the MAC as well as stimulation of cytokine and chemokine formation 
and through progression to fibrosis (47). However, this has mostly been observed in 
animal models. C3 production by kidney endothelial cells has been shown to be induced 
by immune stimulation and can possibly modulate the adaptive immune system (50). 
Tubular epithelial cells are also known to express C3a and C5a receptors and signaling by 
these receptors leads to harmful effects (47). Furthermore, silencing of C3 and C5a 
receptor in mouse models of IRI has been shown to be effective at improving the function 
of the affected kidneys (51-53). Currently, a clinical trial involving eculizumab, a C5 
monoclonal antibody, is ongoing with the goal of reducing DGF in renal transplant 
recipients who have received a kidney from an ECD or SCD donor with a CIT of 18-40 
hours (ClinicalTrials.gov identifier: NCT 01919346). C3 and C5 are both important 
components of the complement cascade in all three pathways and may represent potential 
targets in the amelioration of IRI.  
Other factors involved in innate immunity include natural killer (NK) cells, macrophages, 
neutrophils, and T cells. Dendritic cells (DCs) provide an important link between the 
innate and adaptive immune system by acting as professional antigen presenting cells 
(APCs). DCs arrive at the site of injury and then travel to lymph nodes to present 
antigens to T cells (41). The adaptive immune response during IRI at the time of 
transplantation may lead to episodes of acute rejection as well as long-term graft failure 
(54).  
1.3.5 Effect of IRI on Graft Function in Renal Transplantation 
In renal transplantation, IRI is a type of acute kidney injury (AKI) which can lead to 
primary non-function, slow graft function, and DGF (15). In transplantation, there is a 
WIT, CIT, and a reperfusion phase. The WIT is considerably longer in DCD donors as 
there is time during which the organs are not perfused and the donor remains at a 
normothermic temperature. This time generally lasts anywhere from 20 minutes to 1 
hour. A recent study by Salmeron-Rodriguez et al. found that the mean WIT was 24.88 
minutes for Maastricht class III donors (55). In NDD donors, however, this time is very 
short and lasts for only a few minutes. The WIT and CIT create a hypoxic environment 
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where many cellular changes occur leading to cell injury and death. Both phases 
contribute to the damage that occurs during transplantation, and decreasing these times 
leads to lower rates of cellular injury and DGF (28, 56). Although the overall graft 
survival rates are similar between DCD and NDD donor kidneys, the rate of DGF and 
discarded organs are higher in DCD donor kidneys (14, 56). Discard rates of up to 34 
percent have been observed with DCD donors and, therefore, is an important area to 
target to attempt the salvage and protection of these organs (56).  
The need to protect the graft during procurement, transportation, and implantation is 
paramount in order to improve graft function and survival after transplantation. 
Treatment of the graft during these phases as well may lead to lower discard rates, higher 
quality grafts, and lower rates of DGF. The current therapies used around the time of 
transplantation will be further discussed below. 
1.4 Current Treatment of IRI in Renal Transplantation 
Currently, there are a limited number of effective therapies for IRI in transplantation and 
there is a need to develop treatments for IRI in order to improve the organs available for 
transplant and expand the number of organs which can be used. The selection of 
appropriate donors is an essential first step in order to obtain high quality organs, 
however, with the expansion to ECD and DCD donors, more and more marginal grafts 
are being used to increase the supply of organs. A recent FDA workshop on IRI in kidney 
transplantation sought to discuss the current state of knowledge of IRI and its effects on 
kidney transplantation (15). Past and current therapies were discussed at this workshop 
and the need for more research was highlighted. Some of the therapies which have been 
tested clinically include those listed in Table 1. 
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Table 1 Summary of Therapies for the Treatment of IRI in Clinical Kidney 
Transplantation (Continued on page 18) 
Donor Type Treatment Outcomes Reference 
NDD Furosemide vs. no treatment prior 
to reperfusion 
No difference in 
DGF 
(57) 
Deceased 
donors 
Omnibonia (vit. A, B complex, C, 
and E)  vs. no treatment prior to 
reperfusion 
Lower serum Cr up 
to 6 days, but no 
difference thereafter 
(58) 
DCD Pentoxifylline at induction of 
anesthesia in recipients followed by 
once a day for 48h vs placebo 
No difference in 
DGF 
(59) 
DCD Enlimomab (anti-ICAM1 mAb) 3h 
pre-transplant followed by once a 
day for 5 days vs placebo 
No difference in 
DGF 
(60) 
DCD Epoetin-β before transplant and at 
12h, 7 days, and 14 days vs no 
treatment 
No difference in 
DGF or graft 
survival 
(61) 
Deceased 
donors 
EPO-α at time of transplant vs 
placebo 
No difference in 
DGF or SGF 
(62) 
NDD IGF-1 at transplant and then twice a 
day for 6 days vs placebo 
No difference in 
DGF, serum Cr, or 
inulin clearance 
(63) 
DCD Dopamine vs dopamine-1 receptor 
antagonist infusion for 48h 
No difference in 
urine output or 
serum Cr 
(64) 
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Donor Type Treatment Outcomes Reference 
DCD 3 5min cycles of remote ischemic 
conditioning in unilateral lower 
limb (clamping of external iliac 
artery) at time of transplantation vs 
sham procedure 
Reduced serum 
creatinine and 
urinary NGAL, 
increased GFR 
(65) 
DCD YSPSL (blocks leukocyte 
adhesion) vs placebo 
Higher rates of DGF 
in treated group 
(66) 
Living donor Spironolactone 1 day prior and 3 
days post transplant vs placebo 
No difference in 
renal function, but 
decreased urinary 
hydrogen peroxide 
(67) 
Cochrane 
Review of 
RCTs 
Calcium channel blockers (CCBs) 
in the peri-transplant period 
Significant reduction 
of ATN and DGF in 
the treated groups 
(68) 
NDD N-acetylcysteine 1h prior to and 2h 
following angiography to confirm 
brain death vs placebo 
No difference in 
DGF 
(69) 
NDD Methylprednisolone 3h prior to 
procurement vs placebo 
No difference in 
DGF 
(70) 
Deceased 
donors 
Vitamin C added to perfusion 
solution 
No difference in 
DGF 
(71) 
Deceased 
donors 
Human rh-SOD prior to reperfusion 
followed by a 1h infusion 
afterwards vs placebo 
No difference in 
GFR or serum 
creatinine 
(72) 
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Most of the trials mentioned above showed no difference in outcomes or only short term 
effects. Currently, machine perfusion has garnered a lot of interest in clinical trials. 
Machine perfusion involves cannulating the renal artery and vein and perfusing the 
kidney with preservation solution during transport. Previously, kidneys would be placed 
in static cold storage at 4
0
C in preservation solution. The theory behind using machine 
perfusion is that continuous perfusion of the organ will allow for oxygen delivery, 
washout of toxic metabolites, better assessment of the kidney, and maintain the 
microvasculature (73, 74). Despite these potential benefits, machine perfusion, like many 
of the other therapies, has been shown in randomized controlled trials to have no overall 
effect on graft survival (75, 76). However, in two meta-analyses, the rate of DGF has 
been shown to be significantly decreased in the machine perfusion groups (OR 0.64, 
p=0.03, and OR 0.56, p=0.008) (77, 78). These meta-analyses also showed no difference 
in 1 year graft survival between the two groups. Notwithstanding these studies, many 
groups have adopted machine perfusion as the standard of care for DCD and ECD 
kidneys as well as some groups advocating its use for all SCD kidneys. Although 
machine perfusion has not improved graft survival rates, it can still be a valuable tool in 
the reduction of DGF, which leads to increased costs and morbidity, as well as allowing 
for the assessment of organs prior to implantation, and the delivery of novel therapies in 
the ex vivo setting. The variable parameters of machine perfusion are also the subject of 
ongoing study including temperature, pressure, and pulsatility as well as the use of 
oxygen and substrate carrying preservation solutions (79). 
1.5 RNA Interference 
1.5.1 Overview 
RNA interference (RNAi) was described in 1998 by Fire et al. (80). This marked a 
significant discovery for which the Nobel Prize for Physiology or Medicine was awarded 
in 2006. In their landmark paper, it was shown that double stranded RNA containing a 
sense and antisense sequence for a specific gene is much more effective at gene silencing 
than single stranded RNA molecule (either sense or antisense) in C. elegans. They 
hypothesized that the double stranded RNA molecule was required to be incorporated 
into a complex that included a catalytic component as a few molecules lead to significant 
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gene silencing. They also believed that it was likely that the silencing occurred at the 
post-transcriptional level as targeting sequences containing introns did not lead to the 
same amount of gene silencing. Later on, they did indeed show that in RNAi the primary 
DNA sequence was not altered, targeting the upstream operon had no effect on the 
activity of the downstream gene, and that there was a significant decrease in the targeted 
gene transcripts in the nucleus (81). With ongoing research, it was further identified that 
RNAi is important in the normal regulation of many genes with the endogenous 
production of small RNAs. These small RNAs actually account for a significant portion 
of coding regions of the genome for which no function was originally identified and may 
regulate up to 60% of the entire genome by over 1000 different RNA molecules (82, 83). 
In addition, the production of small RNAs by cells was shown to lead to the control of 
viral infection by leading to degradation of viral RNA (82). From this point, it was 
discovered that there are different mechanisms of RNAi which make use of different 
types of RNA molecules including micro RNAs (miRNA), small interfering RNAs 
(siRNA), short hairpin RNAs (shRNA), and PIWI-interacting RNA (piRNA) (83). These 
different mechanisms of RNAi rely on RNA molecules from different sources and 
different cellular machinery, but generally produce similar effects with all relying on an 
Argonaute family protein to help direct it to the correct gene (82, 83). 
1.5.2 RNAi Mechanisms 
The different RNAi mechanisms rely on miRNA, siRNA, and piRNA. miRNAs are 
endogenously produced by the cell. These RNA molecules are initially transcribed as pri-
miRNAs that are at least 1000 nt long and contain single or multiple hairpins where the 
sequences are complimentary to each other. The pri-miRNA is processed in the nucleus 
by Drosha and DGCR8. DGCR8 binds to double stranded RNA and correctly positions 
the RNase Drosha 11 bp from the stem of the hairpin so that it can cleave the pri-miRNA 
into 65-70 bp segments known as pre-miRNA (84). The pre-miRNA is then exported to 
the cytoplasm by Exportin-5 and RanGTP (85). In the cytoplasm, the pre-miRNA is 
further processed by the endoribonuclease Dicer and loaded onto an Argonaute protein as 
a 21 to 25 bp double stranded sequence (82, 83). A third protein, a double-stranded RNA 
binding protein (dsRBP) helps with the activity of Dicer and the loading of the Argonaute 
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protein and together with Dicer and Argonaute, forms the RNA induced silencing 
complex (RISC) (82, 83, 86). Once the RISC is loaded with the double stranded miRNA, 
one strand, the guide strand, is retained while the other strand, the passenger strand, is 
discarded (82, 86). Once all of this has occurred, the RISC can bind to single stranded 
RNA sequences, such as mRNA, which are complimentary to the guide strand which it 
has loaded.  
There are four different Argonaute proteins in humans, and only one, Ago2, has the 
ability to cleave single stranded RNAs when there is perfect complementarity with the 
guide strand. This is known as slicing and does not often occur in miRNA induced gene 
silencing. miRNA are usually complementary to the target over their seed sequence (bp 
2-8) but then bind imperfectly along the remainder of their sequence to the 3’ 
untranslated region (UTR) of mRNAs. Once the RISC is bound to the mRNA, another 
protein, GW182, is recruited to complex and is needed to activate additional cell 
machinery and localization to P bodies (83, 87). In the P bodies the complexes repress 
translation and cause deadenylation and destabilization of the target mRNA rather than 
slicing, as occurs with perfect complementarity (82, 83). As a result of the imperfect 
binding, one miRNA molecule can affect a number of different genes and regulate their 
expression.  
In contrast to miRNAs, siRNAs are completely complementary to the target mRNA 
sequence. siRNAs can be produced endogenously by the cell or may be supplied 
exogenously by viral infection or intentional treatment with synthetic RNA molecules. 
siRNA molecules may occur as 21-25 bp double stranded RNA molecules and be directly 
loaded onto an Argonaute protein, or as shRNA which is first processed by Dicer and 
then loaded onto an Argonaute protein. Once the siRNA molecule is taken up into the 
cytoplasm, it follows the same process as a miRNA molecule would. Due to its perfect 
base pairing with the target mRNA, however, it allows for slicing of the mRNA and gene 
silencing, rather than requiring recruitment of GW182 and translational repression or 
modification of the mRNA (83). Both siRNA and miRNA lead to post transcriptional 
gene silencing. 
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Figure 2 – RNA interference mechanisms involving siRNA and miRNA.  
This figure displays the exogenous administration of siRNA which enters the cell and is 
loaded into the RISC which allows for binding to and slicing of its complementary 
mRNA. Production and processing of miRNA is also shown which leads to silencing 
through destabilization of the target mRNA. Reproduced with permission and copyright 
© from Annual Reviews, Wilson R.C. and Doudna J.A. Annu. Rev. Biophys. 2013, 42: 
217-39. 
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The third type of RNAi involves the use of piRNA. The exact mechanism of piRNA 
induced RNAi is still being studied and is not as well known as that of miRNA or siRNA 
induced RNAi. piRNAs function without the use of Dicer and are initially produced as 
long, single stranded RNAs. These precursors are then exported to an area in the 
cytoplasm known as the nuage which is associated with the nucleus and mitochondria. 
Here they are processed by the endonuclease Zucchini and possibly other endonucleases. 
After processing, the piRNAs are loaded into the RISC complex as 26 – 31 nt molecules 
which are longer than miRNAs or siRNAs. Following formation of the RISC complex, 
the piRNAs can lead to gene silencing in two different ways. First, they can bind the 
complementary mRNA and slice it. In this mechanism, they can enter a ping-pong 
amplification cycle where the sense strand is loaded onto the RISC which cleaves the 
antisense strand. The antisense fragment is then loaded onto the RISC to cleave the sense 
strand. Second, they can translocate to the nucleus and cause transcriptional gene 
silencing by identifying transposable transcripts and recruiting chromatin and DNA 
modifiers. This is thought to be important in the prevention of germ line mutations (83). 
The field of RNAi is constantly expanding and is the subject of intense research. RNAi 
has been applied in many different research settings and the use of siRNA can help to 
identify potential gene targets for the treatment of many different conditions including 
IRI. 
1.5.3 RNAi in Ischemia Reperfusion Injury 
As outlined above, IRI involves many complex cellular events which lead to cell death 
and damage. Therapies targeting IRI in the transplant setting are limited and require 
further investigation and development. RNAi is an exciting new field that may have an 
application in the treatment of IRI. A significant amount of in vitro and small animal 
work has already been performed, as well as some large animal work. Much of the work 
has focused on targeting pathways involved in cell death, inflammation, and immunity. 
Identifying optimal gene targets for silencing in IRI is imperative if a clinically 
significant response is expected. IRI involves many cellular processes and it is difficult to 
recognize which genes may have the greatest effect on not only cell damage and death, 
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but longer term outcomes such as DGF in renal transplantation. The use of RNA micro-
arrays may help to identify which genes are up regulated and during which phase in the 
IRI process. Recent work by Damman et al., has shown that hypoxia, coagulation, and 
complement pathways were enriched in human DCD donors after the first warm ischemic 
time, and that pathways related to endoplasmic reticulum (ER) and mitochondrial stress, 
RNA degradation, and DNA repair were associated with DGF (88). This study was 
unique in that biopsies of the kidneys were taken prior to donation so that they could be 
compared to biopsies taken 45 to 60 minutes following reperfusion. A proposed study 
design involves biopsies taken at 30 minutes and 30 days after transplantation in living 
and deceased donor kidneys to identify potential siRNA targets through microarray 
technology (89). Microarrays have the potential to return a large amount of data and it 
will be important to sort through all of the information so that genes with the most effect 
on IRI can be targeted. 
Table 2 lists genes which have been targeted by siRNA in the research setting in order to 
improve IRI. 
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Table 2 - List of in vivo Studies Using siRNA in the Treatment of Renal IRI 
(Continued on page 26) 
Target Animal Outcome in Treatment Group Reference 
p53 Mice, Rats Attenuation of apoptosis (90, 91) 
IKKβ Rats Decreased BUN, Cr, and cell 
injury on histology 
(92) 
ETaR Rats Decreased BUN, Cr, cell injury 
on histology, and cytokine 
production, and increased NO 
production 
(93) 
S1P(2)R Mice Reduced BUN, Cr, and cell 
injury on histology 
(94) 
RelB Mice Reduced BUN, Cr, cell injury on 
histology, TNFα, and improved 
survival 
(46) 
Fas Mice Reduced apoptosis and cell 
injury on histology, and 
improved survival 
(95) 
C3 Mice Reduced BUN, Cr, cell injury on 
histology, TNFα, and improved 
survival 
(52) 
C5a Mice Reduced BUN, Cr, cytokines, 
and chemokines 
(51) 
Fas and Caspase-8 Mice Reduced BUN, Cr, apoptosis, 
and necrosis 
(96) 
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Target Animal Outcome in Treatment Group Reference 
Caspase-3 and C3 Mice Reduced BUN, Cr, cell injury on 
histology, and improved survival 
(53) 
Caspase-3 and 
Caspase-8 
Mice Reduced BUN, Cr, cell injury on 
histology, and improved survival 
(97) 
Caspase-3 Pigs Reduced apoptosis, 
inflammation, HMGB-1, and cell 
injury on histology, and 
improved renal function 
(98-101) 
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As can be seen, most of these studies involve the use of small animal models. Different 
outcomes were assessed but often included biomarkers of renal function and histological 
examination after sacrifice. This limits the applicability to humans, but avoids the 
increased costs associated with large animal models. These studies have repeatedly 
shown a benefit with the use of siRNA and various gene targets. This research has set the 
stage for a transition to using siRNA in large animal IRI models and eventually, clinical 
trials in humans. 
Caspase-3 siRNA has been used extensively from the in vitro setting to a porcine auto-
transplantation DCD model (98-101). In the auto-transplantation model, Yang et al., 
showed that caspase-3 siRNA protected porcine kidneys up to two weeks following 
transplantation. This DCD model involved injecting caspase-3 siRNA into the kidney 
prior to static cold storage for 24 hours and then again systemically following auto-
transplantation (101). The results of this study are encouraging as progress is being made 
towards human trials. Recently, one human phase I trial (ClinicalTrials.gov identifier: 
NCT00802347) was completed using I5NP (a p53 siRNA) in the prophylaxis of DGF 
following transplantation of DCD kidneys. Results of this trial are not yet available. 
The translation to a clinical setting has been difficult, however, and is the focus of 
ongoing research. There are challenges associated with delivery of the RNA including 
uptake and degradation, as well as off-target and systemic effects. 
1.5.4 Challenges with Translation to a Clinical Setting 
There are many challenges that must be overcome prior to using siRNA in the clinical 
setting. These include the design and delivery of the siRNA as well as efficacy, off-target 
consequences and systemic effects. The design of siRNA needs to take into account 
thermodynamic stability, immunostimulatory motifs, secondary structure, and internal 
repeats in order to create a stable molecule that does not result in degradation nor incite 
an immune response (89, 102). Computer algorithms and known mRNA sequences are 
relied on to identify potential sequences that will be effective at gene silencing. Naked, or 
unmodified siRNA, is often used in research settings. The siRNA can also be chemically 
modified, however, to improve its stability. Chemical modifications include changes at 
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the 2’ position of the ribose by incorporating 2’-O-methylpurines or 2’-O-
fluropyrimidines enhances the stability and effectiveness of the siRNA (89, 103). 
Another modification known as locked nucleic acid (LNA), has been used as well to 
improve stability of the siRNA by linking the 2’ oxygen with the 4’ carbon in the ribose 
through a methylene bridge. This allows for improved binding to its complementary 
sequence (104). 
The delivery of siRNA presents another challenge. While numerous methods of in vitro 
delivery have been developed, it is difficult or impractical to use these methods in an in 
vivo setting. The most common methods for siRNA transfection in the in vitro setting 
make use of lentiviruses, liposomes, nanoparticles, antibodies, and electroporation. These 
delivery methods are employed as naked siRNA is easily degraded and it is difficult to 
get the siRNA across the cell membrane to where it will have its effect. All of these 
methods have the potential to harm the cells and, in the case of viral transfection, create 
an immunologic response (105). Research continues to be done to improve translation of 
in vitro delivery methods to the in vivo setting.  
In the in vivo setting, delivery of naked siRNA has been successful with hydrodynamic 
injection into the tail vein in mice (106). This method involves the injection of a 
relatively large amount of fluid over a short period of time, leading to a sudden increase 
in the intra-vascular volume and pressure. Although the mechanism is unclear, this is 
then thought to facilitate delivery of RNA or DNA to cells by making them more 
permeable as the liver, which has the largest number of fenestrae in its vessel walls, has 
the highest uptake of the delivered genetic material (106). This method has been 
employed in renal warm ischemia models involving mice in which an improvement in 
renal function and 8-day survival were seen with complement 3 and casapse-3 siRNA 
(53). This approach may not be applicable to the clinical setting, however, given the large 
volume injections. Currently, a number of phase I/II clinical trials in areas other than 
transplantation and IRI are employing delivery methods such as liposomes or using naked 
siRNA in the treatment of diseases such as cancer, hypercholesterolemia, various 
ophthalmologic conditions, and familial adenomatis polyposis (FAP) (105). The only 
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clinical trial involving IRI, as mentioned previously, makes use of naked siRNA 
delivered intravenously following graft implantation. 
After the design and delivery of the siRNA has been considered, the efficacy and safety 
of the molecule must also be determined. The design algorithms used to create the siRNA 
also take into account how effective the molecule should be at silencing. The siRNA 
should be targeted to a sequence that is at least 50 to 75 nt downstream from the start 
codon and should avoid any introns to improve silencing (103). After the siRNA is made, 
however, it must be tested, as the silencing effect which is predicted does not always 
occur. Often, three or more sequences will be designed in order to increase the 
probability of developing an effective molecule that can provide the highest silencing 
efficiency. Testing of the siRNA molecules usually occurs in cell cultures prior to in vivo 
studies as these are less expensive. Use of siRNA in vivo may not show the same results 
however, as the siRNA may be not be taken up by the targeted cells, degraded by 
RNases, cleared by the kidneys, and cause immunologic reactions leading to a reduced 
silencing efficiency (89).  
The safety of siRNAs must be determined before they can be used regularly in clinical 
settings. Off-target effects can result from the siRNA binding to an mRNA other than the 
target mRNA leading to its degradation by the RISC complex, an immune response to the 
siRNA, or toxicity from the delivery vehicle (89). In some cases of non-specific binding, 
the siRNA can act like a miRNA sequence. As stated previously, miRNAs require 
complementarity over their seed sequences, but then bind imperfectly over the rest of the 
sequence and can lead to silencing of a number of different genes. If an siRNA has the 
same bases in the seed sequence location of a miRNA it will bind to the 3` UTR of 
mRNAs other than its target. This effect can be reduced with proper design of the siRNA 
(107). The delivery of siRNAs can also lead to complete occupation of the RISC 
complexes with the exogenous siRNA and not allow normal RNAi through miRNA 
silencing. This may have a wide range of effects that are difficult to predict and avoid 
(89, 107). Certain siRNA molecules can also be immunostimulating and lead to 
activation of the innate immune system which is thought to occur via activation of TLRs. 
This usually occurs with double stranded RNAs that are longer than 30 bp, but can occur 
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with 19 bp sequences as well (108). This effect can either be beneficial if the object is to 
stimulate an immune response, or detrimental, as in the case of IRI, where it is necessary 
to avoid further injury caused by the treatment. The delivery vehicle may also be toxic to 
the cells and this toxicity must be balanced with the ability to achieve adequate uptake 
and gene silencing. Transplantation, however, offers the unique ability to deliver a 
treatment such as siRNA in an ex vivo setting and avoid off-target or systemic effects. 
1.6 Incorporating siRNA Delivery with Machine 
Perfusion 
Due to the issues with delivery of siRNA, it is proposed that machine perfusion may be 
the ideal way to delivery siRNA during the ex vivo phase of transplantation. Machine 
perfusion allows for the intravascular delivery of siRNA to the target organ without 
affecting the entire organism. This also allows for control of the perfusion parameters 
such as pressure and temperature. Clinically, the temperature is set at 4
0
C in order to take 
advantage of the reduced metabolism and better preservation. The hypothermic 
conditions create a cold ischemic insult, however, and it is known that increasing times of 
cold ischemia are associated with an increased risk of DGF(109). Currently, there is 
ongoing investigation into whether or not normothermic or subnormothermic conditions 
may lead to better outcomes (110-112). The advantages of using higher temperatures 
include avoiding the cold ischemic insult and maintaining the normal metabolic function 
of the organ as long as oxygen and nutrients are supplied appropriately. Artificial 
preservation solutions have been developed which include oxygen carriers and recently, 
an acellular hemoglobin named Hemoxycarrier
®
 has been used in a porcine 
autotransplantation model to deliver oxygen and has shown promising results (113). In 
the case of siRNA transfection, it may also be beneficial to use normothermic 
temperatures as opposed to the standard hypothermic conditions to ensure optimal uptake 
by the cells. It has been shown by Brasile et al., that normothermic perfusion lead to 
adequate transfection after 24 hours (114). This was using a viral vector to deliver genetic 
material rather than siRNA. Some work has been done with siRNA delivery to porcine 
kidneys in an ex vivo setting, but only during static cold storage (101).  
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The pressure with which the kidneys are perfused and whether or not it is pulsatile are 
also the subject of ongoing debate. Patel et al., showed that for continuous perfusion, a 
pressure of 75mmHg is better than a pressure of 55mmHg (115). It also appears that 
pulsatility may improve creatinine clearance even if it is preceded by static cold storage 
(79). Integrating the delivery of siRNA with machine perfusion will require the 
determination of optimal temperature and pressure settings to both ensure that adequate 
gene silencing occurs and the organ experiences the most benefit from the machine 
perfusion. This has yet to be studied in depth. 
1.7 Study Rationale 
This project was designed with the purpose of developing porcine siRNAs which are 
effective at silencing their target genes and can be used in the future in a porcine DCD 
model while taking advantage of the benefits of machine perfusion. As the cell death 
pathways are quite redundant, we believe that it is important to target more than one 
pathway in order to achieve a clinically significant effect. We have therefore decided to 
target the intrinsic and extrinsic apoptotic pathways with caspase-3 siRNA as both 
pathways require its activation. We have also targeted the complement pathways with 
complement 3 siRNA as all three pathways converge with its activation. Finally, we have 
targeted the Nfκβ transcription factor pathway with RelB siRNA. In order to prove the 
effectiveness of the siRNA prior to using it in large animal studies, in vitro testing with 
an ischemia reperfusion model was used. A commercially available pig kidney tubular 
epithelial cell line was used throughout the project. The tubular epithelial cells are very 
susceptible to hypoxia and represent an appropriate cell type to treat in an IRI model 
(116). Two in vitro models of IRI were used and included a hypoxia chamber and 
antimycin A. The hypoxia chamber allows for complete control over the oxygen, carbon 
dioxide, and nitrogen concentrations as well as the temperature. Antimycin A is produced 
by Streptomyces sp. and inhibits complex III of the electron transport chain (ETC) (117-
119). Upon inhibition of the ETC, the cell switches to anaerobic metabolism and a 
hypoxic environment is mimicked. These IRI models allowed us to assess the normal 
gene expression in response to hypoxia and re-oxygenation as well as that following 
siRNA transfection.  
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Chapter 2  
2 Materials and Methods 
Before translation to a clinical setting, it is important to prove that novel interventions are 
effective in a laboratory setting. This project was designed to demonstrate that silencing 
genes involved in the apoptotic, inflammatory, and complement pathways is an effective 
method to reduce IRI in an in vitro setting. This was accomplished to provide evidence 
for further studies involving large animals with eventual translation to a clinical setting. 
2.1 Cell Culture 
LLC – PK1 cells (ATCC© CL-101™) were used for all experiments. This is a 
commercially available cell line which has been cultured from pig kidney tubular 
epithelial cells. Cells were cultured in 15mL of medium 199 containing 3% fetal bovine 
serum (FBS) as well as penicillin and streptomycin in 75mL flasks. Cells were used 
between passage 2 and 25 and recovered using 0.05% trypsin for 5 minutes at 37
0
C after 
washing with phosphate buffered saline (PBS).  
2.2 Transfection with siRNA in Untreated Cells 
RNA interference was achieved through the use of siRNA. Three different siRNA 
molecules were obtained (Sigma-Aldrich) for each of Caspase-3, Complement 3, and 
RelB. These sequences contain 3’ dT overhangs and are shown in Table 3. 
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Table 3 - siRNA Sequences 
Gene siRNA sequence (5’ to 3’ sense strand) 
Caspase-3 #1 GUGUUUCUAAAGAAGACCA 
Caspase-3 #2 CUUCUUGUAUGCAUAUUCU 
Caspase-3 #3 CCUUCACAAACUUGAAAUA 
Complement 3 #1 GCAUUGACAUCAAACGGGA 
Complement 3 #2 CAGAUGACUUUGACGAUUA 
Complement 3 #3 GACAAACUGGGUCAGUACA 
RelB #1 CGGCCUUCCUGGAUCACUU 
RelB #2 CGCUGACGCGGGACUCGUA 
RelB #3 GCUACGGAGUGGACAAGAA 
 Transfections in normal, untreated PK1 cells were carried out to determine which of the 
three sequences induced the best gene silencing. Cells were plated in 12 well plates 
(1.5x10
5
) and incubated overnight at 37
0
C to allow them to reach a confluency of 90%. 
PK1 cells were then transfected using Lipofectamine
®
 2000 (Life Technologies). This 
was accomplished by adding 0.5μL to 100μL of OptiMEM® (Life Technologies) and 
incubating at room temperature for 5 minutes. Following this, 1μg of siRNA was added 
along with 100μL of OptiMEM and incubated at room temperature for 20 minutes. This 
was then added to a single well. A ratio of 2µL to 1µg (Lipofectamine
®
 2000 to siRNA) 
was used as this allowed for adequate gene silencing and did not induce cell death. At the 
time of transfection, an additional 300μL of OptiMEM was added, and then after 4 hours, 
500µL of medium 199 containing FBS, penicillin, and streptomycin was added. Cells 
were incubated at 37
0
C overnight. 
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2.3 Hypoxia Chamber Conditions 
The H85 HypOxystation
®
 (HypOxygen) was used to simulate ischemic conditions and 
1.5x10
5
 cells, plated in 12 well plates, were placed in the chamber for 0.5-24h at 1% O2, 
5% CO2, and 94% N2, at 37
o
C in 1mL glucose free Dulbeco’s Modified Eagle Medium 
(DMEM). Experiments were carried out using media which had not be de-oxygenated, as 
well as that which had oxygen removed by bubbling a mixture of nitrogen, carbon 
dioxide, and hydrogen gas through the media for 3 minutes. The hypoxia phase was then 
followed by a re-oxygenation phase for 24h at 21% O2, 5% CO2, and 37
o
C, which 
included changing the media to medium 199 containing FBS, penicillin, and 
streptomycin. A negative control was kept at 21% O2, 5% CO2, and 37
o
C with glucose 
free DMEM during the hypoxic phase with a change in the media to medium 199 
containing FBS, penicillin, and streptomycin during the re-oxygenation phase. 
2.4 Treatment with Antimycin A 
Antimycin A (Sigma-Aldrich
®
) was purchased and re-suspended in 95% ethanol 
according to the manufacturer’s instructions. PK1 cells (1.5x105) were plated in 12 well 
plates and time and dose response experiments were performed to determine the 
conditions which would produce a significant amount of injury. Varying concentrations 
(5 – 200 μM) of antimycin A as well as varying times of exposure (1 – 4 hours) and 
recovery (3 – 24 hours) were used. It was determined that treating the cells with 10μM 
antimycin A in PBS containing Mg
2+
 and Ca
2+
 for 3 hours followed by 3 hours of 
recovery induced a significant amount of apoptosis and cell death while still maintaining 
approximately 60 percent viable cells. The recovery period involved changing the media 
to Medium 199 containing 3% FBS, penicillin, and streptomycin. Negative control cells 
were exposed to 3 hours of PBS containing Mg
2+
 and Ca
2+
, followed by the recovery 
phase in normal media.  
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2.5 Treatment with Antimycin A Following Transfection 
with siRNA 
In order to determine if the different siRNA molecules were effective at protecting the 
cells from injury and death, PK1 cells were transfected 24 hours prior to treatment with 
antimycin A. Once again, PK1 cells (1.5x10
5
) were plated in 12 well plates and incubated 
overnight at 37
0
C. Once at a confluency of approximately 90 percent, the cells were 
transfected with caspase-3, complement 3, and RelB siRNA according to the methods 
outlined above in 2.2. The following combinations of siRNA were used: 
1. Caspase-3 alone 
2. Complement 3 alone 
3. RelB alone 
4. Caspase-3 and complement 3 
5. Caspase-3 and RelB 
6. Complement 3 and RelB 
7. Caspase-3, complement 3 and RelB 
Following transfection, the cells were incubated overnight at 37
0
C and then washed with 
PBS and treated with antimycin A according to the methods outlined in 2.4 using 10μM 
of antimycin A for 3 hours followed by 3 hours of recovery. Following this recovery 
phase, cells were analyzed by flow cytometry, quantitative real-time polymerase chain 
reaction (qPCR), and Western blotting. 
2.6 Flow Cytometry Analysis 
Cells were analyzed following all experiments for apoptosis and viability by flow 
cytometry using the Beckman Coulter FC 500 flow cytometer. Following the recovery 
phase, cells were trypsinized and collected, along with any floating cells in the media, by 
centrifugation at 1500rpm for 5 minutes. Cells were then washed with 1mL of PBS and 
centrifuged at 1500rpm for 5 minutes. Cells were then stained with Annexin V and 
propidium iodide by resuspension in 100μL of Annexin V buffer according to the 
manufacturer’s instructions (BD Biosciences). Cells were then incubated at room 
temperature in the dark for 15 minutes. Following this, 300μL of Annexin V buffer was 
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added and the cells were analyzed by flow cytometry. In order to compensate correctly 
between the channels, two extra samples were included; one stained only with Annexin V 
and one stained only with propidium iodide. An unstained control was also included to 
account for any baseline fluorescence of the cells. No gates were used on the cells as all 
of the cells, regardless of size, were important for the analysis. 
2.7 Quantitative Real-time PCR 
RNA was isolated immediately following the recovery phase using TRIzol® (Life 
Technologies). According to the manufacturer’s instructions, 500μL of TRIzol® was 
added to the adherent cells and gently pipetted up and down a few times and then 
collected into a 1.5mL Eppendorf tube. At this point the solution was either stored at -
20
0
C for future use or used immediately by adding 100μL of chloroform, inverting by 
hand for 15-30 seconds and incubated at room temperature for 2-3 minutes. Samples 
were then centrifuged at 12,000g for 15 minutes at 4
0
C and the supernatant transferred to 
a new 1.5mL Eppendorf tube to which 250μL of isopropanol was added. The samples 
were inverted gently and then incubated at room temperature for 10 minutes. This was 
followed by centrifugation at 12,000g for 10 minutes at 4
0
C and the supernatant was 
discarded. The pellet was washed with 500μL of 75% ethanol, resuspended, and 
centrifuged at 7,500g for 5 minutes at 4
0
C. The supernatant was discarded and the pellet 
air dried. Once dried, an appropriate amount (depending on pellet size) of nuclease free 
water was added to the RNA pellet and incubated at 55-60
0
C for 10 minutes. At this point 
the RNA was either used immediately or stored at -80
0
C for future use. In order to ensure 
good quality RNA, 1μL of the RNA sample was analyzed by gel electrophoresis using a 
1% agarose gel containing ethidium bromide. 
Once isolated, the RNA was used to create complimentary DNA (cDNA). The RNA 
concentration was measured by diluting 2μL of the RNA sample in 98μL of nuclease free 
water and detecting the absorbance at 260 and 280 nm with a spectrophotometer. The 
A260/A280 ratio was calculated to identify issues with RNA quality. cDNA was then 
created by using 3μg of RNA. The RNA was combined with 0.5μg of Oligo dT primers, 
and nuclease free water (to a volume of 13μL) and incubated at 700C for 10 minutes 
followed by a quick chill on ice. Following this, 3.5μL of nuclease free water, 2μL of 
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10X reverse transcriptase buffer, 1μL of 10nM dNTPs, and 0.5μL of M-MuLV reverse 
transcriptase (New England Biolabs) were added. The samples were then incubated at 
42
0
C for 50 minutes and then 70
0
C for 15 minutes to inactivate the reverse transcriptase. 
The cDNA was then stored at 4
0
C for future use. 
Following the formation of cDNA, quantitative real-time PCR (qPCR) was used to 
determine the relative expression of the genes of interest. cDNA was diluted 10 times 
with nuclease free water and used in the qPCR reactions. This was combined with 5μL of 
SensiFAST™ SYBR® No-ROX reagent (Bioline), 200nmol of forward and reverse 
primers, and 2.3μL of nuclease free water for a complete reaction volume of 10μL. 
Primer and cDNA concentrations were optimized using varying concentrations of both. 
The reactions proceeded as outline below: 
1. 950C for 2 minutes 
2. 950C for 10 seconds 
3. 600C for 10 seconds          repeat 39x 
4. 720C for 20 seconds 
5. 950C for 30 seconds 
6. 600C for 10 seconds          melt curve 
7. 950C end 
Primers were designed using Primer-BLAST (NCBI) with a targeted annealing 
temperature of 60
0
C (120). The primer pairs are shown in Table 4. 
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Table 4 - Primer Sequences for qPCR 
Gene Primers (5’ to 3’) 
β-actin Forward 
TCCACGAAACTACCTTCAACTC 
Reverse 
GATCTCCTTCTGCATCCTGTC 
Caspase-3 Forward 
TCTAAGCCATGGTGAAGAAGGAAAAA 
Reverse 
GGGTTTGCCAGTTAGAGTTCTACAG 
Complement 3 Forward 
GCGCAGCATCAATAAGGCAAGAGA 
Reverse 
CAGCGCACAATAGGAGGGACAGAG 
RelB Forward 
ACGTACCTGCCTCGGGACCAC 
Reverse 
CCAGGCCAGGGAGGGATACAGT 
 
 qPCR products were analyzed using gel electrophoresis with a 1% agarose gel 
containing ethidium bromide to ensure the presence of only one band at the expected 
length. Bio-Rad CFX Manager
TM
 3.1 software was used to analyze qPCR results using 
the ∆∆Ct method with β-actin as the housekeeping gene. The following formula was 
used: 
∆CT (test) = CT (target, test) – CT (reference, test) 
∆CT (control) = CT (target, control) – CT (reference, control) 
∆∆CT = ∆CT (test) – ∆CT (control) 
Normalized expression ratio = 2
-∆∆C
T
 
 Results are displayed as relative expression with the control group arbitrarily set at 1.  
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2.8 Western Blotting 
Western blotting was performed to assess protein expression following injury by 
antimycin A and gene silencing using siRNA. Protein was isolated from PK1 cells using 
radioimmunoprecipitation assay (RIPA) buffer containing the protease inhibitor 
phenylmethylsulfonyl fluoride (PMSF) by pipetting up and down a number of times and 
then incubating on ice for 15 minutes. Samples were then centrifuged at 12,000g for 10 
minutes at 4
0
C. The supernatant was then transferred to a new Eppendorf tube and either 
used immediately or stored at -80
0
C for future use.  
Protein concentration was then measured using the Bradford assay by adding 2μL of the 
sample to 98μL of Bradford buffer and vortexing. Concentration was then measured 
using a spectrophotometer and measuring the absorbance at 595nm and subtracting the 
absorbance of the blank. The protein samples were then combined with an appropriate 
amount of 5x protein binding buffer and boiled for 10 minutes. 
SDS-PAGE was then used to separate proteins. The components of the gels are shown in 
Table 5. 
Table 5 - SDS Polyacrylamide gels used for Western blots 
 12% gel Stacking gel 
ddH2O (mL) 1.7 3.4 
30% Bis-acrylamide mix (mL) 2.0 0.83 
1.5M Tris (pH8.8) (mL) 1.3 1.0M Tris (pH 6.8) 
0.63 
10% SDS (mL) 0.05 0.05 
10% APS (mL) 0.05 0.05 
TEMED (mL) 0.002 0.005 
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After the gels had been made, 30μg of protein was loaded into the stacking gel and run at 
80V until it was through the stacking gel and then run at 120V through the rest of the gel 
in running buffer. Once the bands had reached the end of the gel, the electrophoresis was 
stopped and the stacking gel removed from the running gel. The running gel was then 
placed next to a nitrocellulose membrane. This was then placed in a tank of transfer 
buffer and run at 100V for 1 hour. Buffer composition is listed in Table 6. 
 
Table 6 - Western blot buffer composition 
10X Transfer Buffer 
Tris 30.3g 
Glycine 144.1g 
ddH2O 1L 
5X Running Buffer 
Tris 15g 
Glycine 72g 
SDS 5g 
ddH2O 1L 
1X running buffer was prepared using 200mL of 5X running buffer and 800mL of 
ddH2O. 1X transfer buffer was prepared using 100mL of 10X transfer buffer, 200mL of 
methanol, and 700mL of ddH2O.  
Following protein transfer, the membrane was blocked with 5% milk for 1 hour at room 
temperature. The primary antibodies were then diluted in TBS-T (Table 6), added to the 
membrane, and incubated overnight at 4
0
C on a shaker. 
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Table 7 - Primary antibodies used in Western blots. 
Primary antibody Dilution in TBS-T 
β-actin (mouse monoclonal) 
Santa Cruz Biotechnology
®
 Inc. 
1:5000 
Caspase-3 (rabbit polyclonal) 
Santa Cruz Biotechnology
®
 Inc. 
1:2000 
 
Following incubation overnight, the primary antibodies were removed and the membrane 
washed with TBS-T three times for 10 minutes each. The secondary antibodies (Table 7) 
were then added to the membrane and incubated at room temperature for 1 hour on a 
shaker. The secondary antibodies were then removed and the membrane washed with 
TBS-T three times for 10 minutes each. 
Table 8 - Secondary antibodies used in Western blots. 
Secondary antibody Dilution in TBS-T 
Goat anti-mouse 
Santa Cruz Biotechnology
®
 Inc. 
1:5000 
Goat anti-rabbit 
Santa Cruz Biotechnology
®
 Inc. 
1:5000 
The membranes were then analyzed by enhanced chemiluminescence using Clarity
TM
 
Western ECL blotting substrate (Bio-Rad). Membranes were exposed using the 
FluorChem
TM
 M System (Protein Simple
®
) and densitometry was used to quantitatively 
analyze the blots. β-actin was used as a reference. 
2.9 Statistical Analysis 
All statistical analyses were completed using IBM
®
 SPSS
®
 for Windows, Version 24.0. 
One way ANOVA was used to compare means between more than two groups with 
Tukey post hoc analysis. The Kruskal-Wallis test was used to compare means between 
more than two groups if the data was non-parametric. Student’s t test was used to 
compare means between two groups. Results were considered significant with a p value 
of < 0.05. All experiments were completed in triplicate. 
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Chapter 3  
3 Results 
3.1 Validation of Gene Silencing by siRNA 
Three separate siRNA sequences were obtained from Sigma-Aldrich for each target gene. 
Preliminary experiments were performed to identify the sequences which produced the 
most silencing. This included both qPCR to assess the effect on the mRNA as well as 
flow cytometry to assess uptake of the siRNA into the cell. 
3.1.1 qPCR siRNA Silencing Results 
qPCR results for caspase-3, complement 3, and RelB siRNA in normal PK1 cells are 
shown in Figures 3, 4, and 5.  
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Figure 3 - Silencing of caspase-3 with siRNA.  
Three sequences were obtained in order to identify which was most effective. Relative 
expression for the control sample was arbitrarily set at 1. Caspase-3 # 1 provided the 
most silencing and was used in further experiments. * p < 0.05 compared to control, n = 
3, error bars: SEM +/-1. 
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Figure 4 - Silencing of complement 3 with siRNA.  
Three sequences were obtained in order to identify which was most effective. Relative 
expression for the control sample was arbitrarily set at 1. C3 # 1 provided the most 
silencing and was used in further experiments. * p < 0.05 compared to control, n=3, error 
bars: SEM +/- 1. 
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Figure 5 - Silencing of RelB with siRNA.  
Three sequences were obtained in order to identify which was most effective. Relative 
expression for the control sample was arbitrarily set at 1. RelB # 3 provided the most 
silencing and was used in further experiments. * p < 0.05 compared to control, n=3, error 
bars: SEM +/- 1. 
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3.1.2 Western Blot Results Following siRNA Silencing 
Silencing of caspase-3 using siRNA was confirmed using Western blots. Figure 6 shows 
a clear decrease in caspase-3 following transfection with all of the caspase-3 siRNA 
sequences. This proves that the siRNA is effective at reducing both the mRNA levels as 
well as the protein levels of caspase-3. 
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Figure 6 - Western blot using protein isolated from PK1 cells following transfection 
with caspase-3 siRNA. 
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3.1.3 Flow Cytometry Results of Transfection Efficiency 
One of the caspase-3 siRNA molecules was labeled with Dy547 fluorescent dye in order 
to assess cellular uptake following transfection. A ratio of 2μL of Lipofectamine® 2000 to 
1μg of Dy547 labeled Caspase-3 siRNA was used in these experiments. Flow cytometry 
was used to determine the percentage of cells containing the labeled siRNA (Figure 7). 
Transfected cells were also stained with Annexin V and propidium iodide to ensure that 
the transfection with siRNA did not cause an increase in cell death (Figure 8). 
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Figure 7 - Flow cytometry histogram with transfected PK1 cells.  
Cells which have not been transfected, left, and is used as a control, and PK1 cells which 
have been transfected with Dy547 labeled caspase-3 siRNA, right. Uptake is excellent at 
close to 100 percent using the ratio of 2μL Lipofectamine® 2000 to 1μg of siRNA. This 
allowed us to be confident in the fact that we were able to have good cellular uptake of 
the siRNA molecules. 
 
 
 
 
Dy547 Dy547 
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Figure 8 – Viability of PK1 cells following transfection.  
PK1 cells which have not been transfected, left, and PK1 cells transfected with caspase-3 
siRNA using Lipofectamine
®
 2000, right. Cells were stained with Annexin V and 
propidium iodide. This result shows that the number of viable cells (93% vs 94%) were 
very similar between the non-transfected and transfected cells. 
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3.2 Hypoxia Chamber Experiments 
The H85 HypOxystation
®
 (HypOxygen) was used to induce hypoxia in order to simulate 
IRI. This hypoxia chamber was thought to be the ideal IRI model for in vitro experiments 
as it can be used to closely replicate the conditions encountered in IRI. This chamber 
allowed for reliable monitoring and control of temperature and of the concentrations of 
oxygen, carbon dioxide, and nitrogen. Following exposure to the hypoxic environment, 
cells were allowed to recover in normal conditions to simulate a reperfusion phase. 
3.2.1 Flow Cytometry 
Cells were collected for analysis by flow cytometry following re-oxygenation. Annexin V 
and propidium iodide were used to assess for apoptosis and necrosis respectively. 
Experiments were carried out using different hypoxia times and are shown below 
(Figures 9 and 10). A hypoxic time of 24 hours was repeated three times to confirm the 
data (Figure 11). 
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Figure 9 - Flow cytometry results from the hypoxia chamber.  
Normal PK1 cells which were used as a negative control (A), and PK1 cells which have 
been exposed to hypoxia for 15 hours (B), 18 hours (C), and 24 hours (D). This was 
followed by a re-oxygenation phase of 24 hours. Cells were stained with Annexin V and 
propidium iodide. Even with long hypoxic times (24h), there is no difference in the 
number of viable cells between the negative control and the cells which were exposed to 
the hypoxic environment.  
A B 
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Figure 10 - Flow cytometry results from the hypoxia chamber. 
Normal PK1 cells which were used as a negative control (A) and PK1 cells which have 
been exposed to hypoxia for 16 hours (B), and 24 hours (C) followed by a re-oxygenation 
phase of 24 hours. Cells were stained with Annexin V and propidium iodide. Again, these 
results show that there is no difference in the cells which were exposed to the hypoxic 
environment and the negative control cells which were kept at normal conditions. 
A B 
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Figure 11 – Combined flow cytometry results from PK1 cells placed in the hypoxia 
chamber for 24 hours.  
Following the hypoxic insult, cells were allowed to recover in normal media in a re-
oxygenation phase that lasted 24 hours in order to simulate reperfusion. There was no 
significant difference found between the groups. p=0.596, n=3, error bars: +/- 1 SE. The 
hypoxia chamber experiments were repeated multiple times and the combined 24h results 
are shown here to show that even with long hypoxic times, the number of apopotic cells 
are not significantly different between the groups. Shorter times were used, as indicated 
above, and repeated, but again no difference was seen. This lead to a change in the IRI 
model as this model was not producing cell death in this cell line. 
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3.2.2 qPCR 
As seen in figure 12, there was lower expression of caspase-3 seen in PK1 cells which 
had been placed in the hypoxia chamber. This was contrary to what was expected based 
on the length of time the cells were present in the hypoxia chamber. Various hypoxic (30 
minutes – 48 hours) and re-oxygenation (3 hours – 24 hours) times were used over the 
course of these experiments to identify the optimal conditions required to induce cell 
injury and death, however, very inconsistent results were obtained. Due to the unexpected 
flow cytometry and qPCR results, a different IRI model was required. 
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Figure 12 - qPCR results from PK1 cells placed in the hypoxia chamber for 24 
hours.  
Following the hypoxic insult, cells were allowed to recover in normal media in a re-
oxygenation phase that lasted 24 hours in order to simulate reperfusion. p=0.333, n=2, 
error bars: SEM +/- 1.  
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3.3 Antimycin A Model of Ischemia Reperfusion Injury 
Due to the difficulties with using the hypoxia chamber to induce IRI in an in vitro setting, 
a second IRI model had to be used. Antimycin A inhibits complex III of the electron 
transport chain and effectively induces a hypoxic environment. Prior to transfection with 
siRNA, optimal conditions had to be established for its use. 
3.3.1 Flow Cytometry and Dose Response Experiments 
Various exposure times and concentrations of antimycin A were used in order to obtain a 
significant injury from which a difference could be observed following treatment with 
siRNA. Initially exposure times were maintained between 1 and 4 hours and followed by 
a recovery phase that lasted up to 24 hours. This produced either almost no injury at 
lower concentrations, or too much cell death at higher concentrations (Figure 10). As 
antimycin A must be dissolved in 95 percent ethanol, a control exposing cells to an 
equivalent volume of 95 percent ethanol was included. Due to the small volume, no 
difference from the negative control was observed (Figure 13). The model was then 
adjusted to include a shorter recovery time and improved results were obtained with an 
increased number of viable cells (Figure 14). 
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Figure 13 – Antimycin A experiments. 
Normal PK1 cells which served as a negative control (A). PK1 cells exposed to 2μL of 95 
percent ethanol (B). Media was replaced with PBS which did not contain antimycin A 
during the treatment phase in both of these controls. PK1 cells treated with 2.5μM 
antimycin A for 3 hours followed by 24 hours of recovery (C) and PK1 cells treated with 
10μM antimycin A for 3 hours followed by 24 hours of recovery (D). Cells were stained 
with Annexin V and propidium iodide. 
A B 
C D 
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Figure 14 – Antimycin A experiments. 
Normal PK1 cells (A) and PK1 cells treated with 10μM antimycin A for 3 hours followed 
by 3 hours of recovery (B). Cells were stained with Annexin V and propidium iodide. 
 
 
 
 
 
 
 
 
 
A B 
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From these experiments, an exposure time to antimycin A of 3 hours followed by a 3 
hour recovery phase in normal media was used. Due to the small volume of ethanol used 
(which was necessary to dissolve the antimycin A), it did not have an effect on cell death. 
Also, the cells treated with antimycin A had the media changed to PBS during the 
exposure time to ensure that there was no available glucose, and the negative control 
confirmed that this did not have an effect on cell death. 
3.3.2 Flow Cytometry and Adjustment of siRNA:Lipofectamine 
Transfection Ratios 
As shown above, using a ratio of 2μL of Lipofectamine® 2000 to 1μg of siRNA allowed 
us to obtain a transfection efficiency close to 100 percent without causing obvious cell 
injury or death (Figures 7 and 8). However, when PK1 cells were transfected with siRNA 
24 hours prior to treatment with antimycin A, an increase in apoptosis was observed 
compared to cells which were only treated with antimycin A and not transfected (Figure 
15). This lead to a need to re-adjust the Lipofectamine
®
 2000 to siRNA ratio as the 
liposome is known to be toxic to cells. Caspase-3 Dy547 labeled siRNA was again used 
to obtain an optimal transfection ratio for use with antimycin A and results are shown in 
Figure 16. Transfected cells were also stained with Annexin V and propidium iodide and 
analyzed using flow cytometry to ensure that cells survived following transfection and 
treatment with antimycin A. PK1 cells were transfected with caspase-3 siRNA and then 
treated with 10μM antimycin A for 3 hours followed by 3 hours of recovery. Results are 
shown in Figure 17. 
 
 
 
 
61 
 
 
Figure 15 – Antimycin A treated PK1 cells following transfection with siRNA. 
A B 
C 
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Normal PK1 cells (A). PK1 cells treated with 10μM antimycin A for 3 hours followed by 
3 hours of recovery (B) and PK1 cells treated with antimycin A in the same way after 
transfection with caspase-3 siRNA (C). PK1 cells treated with 10μM antimycin A for 3 
hours followed by 3 hours of recovery from a seperate experiment (D) and PK1 cells 
treated with antimycin A after transfection with scrambled siRNA (E). Cells were stained 
with Annexin V and propidium iodide. 
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Figure 16 – Adjusted siRNA to Lipofectamine® 2000 ratios.  
Varying ratios of Dy547 labeled caspase-3 siRNA and Lipofectamine
®
 2000. Non-
transfected control (A), 1μL Lipofectamine® 2000 to 1μg siRNA (B), 0.5μL 
Lipofectamine
®
 2000 to 1μg siRNA (C), and 0.25μL Lipofectamine® 2000 to 1μg siRNA 
(D). As the ratio decreased, there was less uptake, but this need to be weighed against the 
issues with toxicity of the liposome. 
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Figure 17 - Varying ratios of caspase-3 siRNA and Lipofectamine
®
 2000 in 
antimycin A treated PK1 cells.  
Non-transfected control (A), 1μL Lipofectamine® 2000 to 1μg siRNA (B), 0.5μL 
Lipofectamine
®
 2000 to 1μg siRNA (C), and 0.25μL Lipofectamine® 2000 to 1μg siRNA 
(D). Cells were stained with Annexin V and propidium iodide. This shows that the ratio 
of Lipofectamine
®
 2000 to siRNA had an effect on apoptosis in cells that were both 
transfected and exposed to antimycin A and this needed to be taken into account. 
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Following these experiments, it was decided to proceed with a 0.5μL Lipofectamine® 
2000 to 1μg siRNA ratio as this provided us with an adequate transfection efficiency 
(83%) and showed a benefit in terms of cell survival when cells were treated with 
antimycin A. This ratio was used for all future experiments. 
3.4 Antimycin A and siRNA Experiments 
Following the development of an adequate IRI model using antimycin A, PK1 cells were 
transfected with caspase-3, complement 3, and RelB siRNA alone or in combination 24 
hours prior to treatment with antimycin A. The cells were treated with Antimycin A for 3 
hours followed by 3 hours of recovery in normal medium and then collected for flow 
cytometry analysis as well as RNA isolation. 
3.4.1 Gene Expression of Caspase-3, C3, and RelB 
RNA was isolated to assess the effect on gene expression during treatment with 
antimycin A and transfection with siRNA. RNA was reverse transcribed to cDNA and 
qPCR performed to identify relative expression of caspase-3, complement 3, and RelB. 
Results are shown in Figures 18, 19, and 20 respectively. All of the siRNAs showed a 
reduction in relative expression of their respective genes compared to their negative 
controls. Only caspase-3 expression was significantly elevated in the positive control 
relative to the negative control following treatment with antimycin A, however. 
Complement 3 expression was actually significantly decreased after cells were treated 
with antimycin A. 
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Figure 18 - Caspase-3 expression in PK1 cells following treatment with antimycin A 
after transfection with siRNAs listed. 
* p < 0.05 compared to positive control (antimycin A), n=3, error bars: SEM +/- 1. 
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Figure 19 - Complement 3 expression in PK1 cells following treatment with 
antimycin A after transfection with siRNAs listed. 
* p < 0.05 compared to positive control, n=3, error bars: SEM +/- 1. 
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Figure 20 - RelB expression in PK1 cells following treatment with antimycin A after 
transfection with siRNAs listed. 
* p < 0.05 compared to positive control, n=3, error bars: SEM +/- 1. 
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3.4.2 Flow Cytometry Results Following Treatment with Antimycin 
A and siRNA Transfection 
Flow cytometry was used to assess for apoptosis and cell viability using Annexin V and 
propidium iodide staining. Results are shown in Figures 21 and 22 and Table 9. A 
significant reduction in apoptosis was seen when caspase-3 and RelB siRNA was used 
(either alone or in combination). The relative risk reduction was quite pronounced as 
shown in Table 9. A synergistic effect was not observed when two or three different 
siRNAs were used in combination. Complement 3 siRNA did not provide any benefit in 
terms of reduction of apoptosis or increased cell viability.  
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Figure 21 - A representative flow cytometry result of PK1 cells following treatment 
with antimycin A and transfection with caspase-3 siRNA. 
PK1 cells treated with antimycin A for 3 hours followed by a recovery phase of 3 hours 
(A) and PK1 cells following transfection with Caspase-3 siRNA followed by treatment 
with antimycin A (B). Cells were stained with Annexin V and propidium iodide. This 
shows a large decrease in the percentage of apoptotic cells in the siRNA treated group. 
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Figure 22 - Percentage of apoptotic cells as measured by flow cytometry using 
Annexin V staining. 
All groups, except for the negative control, were treated with antimycin A for 3h 
followed by 3h of recovery. Cells were transfected with the indicated siRNA 24h prior to 
treatment with antimycin A. * p < 0.05 compared to positive control (antimycin A), n=3, 
error bars: SEM +/- 1. Caspase-3 and RelB siRNA were effective alone and in 
combination in reducing apoptosis in the antimycin A treated cells. No synergistic effect 
was seen, however. 
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Table 9 - Relative risk reduction of apoptosis after RNAi in PK1 cells treated with 
antimycin A.  
n=3 for all samples, one way ANOVA with Tukey post hoc analysis used for statistical 
analysis. 
Sample Relative Risk Reduction (%) P value 
Caspase-3 siRNA 46.6 0.019 
C3 siRNA 13.9 0.968 
RelB siRNA 42.8 0.038 
Caspase-3 and C3 siRNA 42.2 0.043 
Caspase-3 and RelB siRNA 43.7 0.034 
C3 and RelB siRNA 35.6 0.129 
Caspase-3, C3, and RelB siRNA 44.3 0.029 
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Chapter 4  
4 Discussion 
There is a significant need for more donor kidneys in order to address the large number of 
patients who are currently waiting for a kidney transplant. In Canada in 2012, there were 
2469 patients on the waiting list for a renal transplant with only 1054 transplants 
performed (2). The donor pool was traditionally limited to SCD donation in order to 
ensure high quality grafts. Recently, however, the donor pool is being expanded to 
include DCD and ECD donors in order to address the need for more available donor 
kidneys. These organs are of lower quality given the co-morbidities present in ECD 
donors and the prolonged WIT in DCD donors. Much advancement has been made in 
transplantation since the first successful kidney transplant which has made transplantation 
possible by overcoming issues with rejection. There is a lack of effective therapies 
targeted at improving the quality of the graft during procurement, transport, and 
implantation, however. This is an important area of research, especially in kidneys from 
DCD donors where there is a prolonged period of decreased perfusion followed by no 
perfusion. 
IRI is unavoidable during renal transplantation and can cause significant cell damage and 
death. This is especially prominent in DCD donation due to the lengthened WIT and 
leads to an increased rate of DGF. IRI is a complex process that involves the activation of 
many different molecular pathways. Most therapies targeted at IRI have not proceeded 
past the experimental stage, unfortunately. Machine perfusion is being used clinically and 
involves perfusing the kidney with perfusion solution prior to implantation. This has been 
shown to decrease the rate of DGF, but has not increased overall graft survival (77, 78). 
Novel therapies for IRI are needed to increase the amount and quality of available organs 
for transplantation in order to adequately treat the many patients who are on the waiting 
list. 
A lot of work has been done in the in vitro setting as well as small animals to develop 
therapies for IRI. One area of research has focused on the use of RNAi to target specific 
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genes involved in the cellular pathways which are up-regulated in IRI. RNAi has proven 
to be very useful in these models; however, the translation to a clinical setting has been 
difficult due to issues around the stability and delivery of these small RNA molecules as 
well as potential off-target effects. Transplantation does offer the possibility of treating 
the organ in an ex vivo setting where off target effects can be minimized and conditions 
can be closely monitored. More research needs to be performed in large animals before 
this can be fully implemented in a clinical setting. 
 This project was designed with the intent of developing effective porcine siRNAs in an 
in vitro setting which could be used in future large animal ex vivo and in vivo 
experiments. The use of RNAi in large animal transplantation models has been limited to 
the targeting of apoptosis. Given the complex and redundant pathways involved in cell 
damage during IRI, however, we identified a need to target multiple pathways in order to 
enhance the treatment effect. Previous work using mice IRI models has shown a benefit 
to combining caspase-3 and complement 3 siRNA (53), as well as caspase-3 and caspase-
8 siRNA (97). For this reason we have targeted caspase-3 (apoptosis), complement 3 
(innate immunity), and RelB (transcription factor involved in the inflammatory response). 
Prior to use of these combinations in a large animal model, it was important to ensure the 
effectiveness of the siRNAs in an in vitro IRI model. With the future use of a porcine 
model in mind, it was decided to use PK1 cells which are pig kidney tubular epithelial 
cells. The tubular epithelial cells are susceptible to ischemia and the PK1 cell line is 
commercially available. 
4.1 siRNA Development and Testing 
Caspase-3, complement 3, and RelB siRNA sequences were obtained from Sigma-
Aldrich
®
 and were tested in normal PK1 cells. All of these genes showed constitutive 
expression. Most of these sequences provided some form of gene silencing and the best 
one from each group was chosen to be used in further experiments. The level of silencing 
was excellent for the sequences chosen as it was around 80 percent for caspase-3 and 
complement 3, and 70 percent for RelB in these normal cells. There was no obvious 
effect on the cellular morphology following transfection and silencing and flow 
cytometry was performed to ensure that the transfection did not induce any cell death 
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(which was confirmed). A Western blot was performed following caspase-3 transfection 
to ensure that the silencing effect extended to the protein level and was not only limited 
to mRNA expression. This was confirmed as well. The development of effective siRNA 
molecules was essential for the success of the rest of the experiments undertaken.  
4.2 Hypoxia Chamber 
In the past homemade chambers have been used to create hypoxic environments by 
continuously flushing the chambers with nitrogen or a combination of gases such as 
nitrogen, carbon dioxide, and hydrogen. These chambers may be unreliable and cannot 
always be monitored closely. The hypoxia chamber used in these experiments was a 
specialized chamber from HypOxygen and provided a controlled environment where the 
temperature, humidity, and concentration of oxygen, carbon dioxide, and nitrogen could 
be controlled and closely monitored. This hypoxia chamber was thought to be able to 
provide the optimal in vitro model for IRI as published studies that have made use of in 
vitro IRI models often use either a homemade version of an anaerobic chamber or 
antimycin A to induce hypoxia (121). Unfortunately, results obtained from the hypoxia 
chamber experiments did not align with what was expected. The PK1 cells which were 
used were very resistant to hypoxia and showed no obvious morphological changes even 
after 24 hours at 1 percent O2. The experiments were adjusted many times in order to 
determine which variables were important in developing a reproducible amount of 
cellular injury and death. This was accomplished by varying times in the hypoxia 
chamber as well as re-oxygenation times after the cells were exposed to hypoxia. The 
type of medium was also changed to either include glucose or not, as well as to de-
oxygenate or not prior to use in the hypoxia chamber. Additionally, cell confluence from 
60 to 90 percent was used. In each case, the PK1 cells remained quite resistant to hypoxia 
and there was not a significant amount of cell death induced by using the chamber. After 
a number of experiments it was decided that a more reliable model of IRI was needed for 
the in vitro experiments.  
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4.3 Antimycin A 
This prompted the switch to using antimycin A which is molecule produced by 
Streptomyces sp. and inhibits complex III of the electron transport chain and induces a 
hypoxic state (117-119). Antimycin A has been used effectively as a model for IRI in 
other studies (43, 121). Experiments were performed to produce an optimal model that 
induced cell death while still ensuring that a significant percentage of cells remained 
alive. The medium was changed to PBS during the treatment with antimycin A to try and 
produce an environment that mimicked that which occurs in transplantation when there is 
no perfusion and a lack of glucose. The PK1 cells were found to be quite susceptible to 
the antimycin A and the cell injury appeared to worsen with the recovery phase in 
normal, glucose containing, medium. If the cells were allowed to recover for 24 hours, 
cell death was much more pronounced than if only 3 hours were allowed for recovery. 
The recovery phase was used to simulate reperfusion. After treatment with antimycin A, 
most dead or dying cells were either in early apoptosis (Annexin V positive, propidium 
iodide negative) or early necrosis/late apoptosis (both Annexin V and propidium iodide 
positive). There was not a significant amount of necrosis seen (Annexin V negative, 
propidium iodide positive). 
Once this model had been developed, transfection with siRNA was performed to identify 
the best time for transfection and examine how the cells reacted to both transfection and 
treatment with antimycin A. It was found that the best time for transfection was the day 
prior to treatment with antimycin A. This ensured that the transfection time was adequate 
and that the effect would be seen in the mRNA and protein expression. It was important 
to have the transfection as close to the treatment with antimycin A as possible to better 
mimic the clinical scenario and to ensure that the non-transfected negative control did not 
become overgrown and experience cell death due to overcrowding. 
Although the transfection protocol which had been developed to test the siRNA did not 
produce any significant amount of cell death, it was noted that when combined with 
antimycin A treatment, more cell death occurred than with antimycin A treatment alone. 
This was thought to be due to the use of the liposome Lipofectamine
®
 2000 which can be 
toxic to cells and induce cell death. The amount of liposome needed to be decreased 
77 
 
therefore in order to ensure that additional cell death was not caused by its use. Different 
ratios were then used in order to identify a ratio which would allow for an adequate 
transfection efficiency and gene silencing, but not be harmful to the cells. This was 
achieved and a ratio of 1μL of Lipofectamine® 2000 to 2μg siRNA was used. 
4.4 Antimycin A and siRNA Transfection 
Once the IRI model had been developed and reliably induced injury and cell death in the 
PK1 cells, experiments were performed to assess the efficacy of the three siRNAs which 
had been chosen (caspase-3, complement 3, and RelB). It was observed that all of the 
genes were silenced compared to the positive and negative controls. Only caspase-3 and 
RelB showed any benefit in terms of reducing apoptosis and increasing the percentage of 
viable cells (Figure 19 and 20). Caspase-3 silencing produced a benefit when silenced 
alone or in combination with complement 3 and RelB. There was a benefit seen when all 
three target genes were silenced as well. Caspase-3 is important to the intrinsic and 
extrinsic apoptotic pathways and it makes sense that silencing of this gene will lead to 
improved cell survival. Caspase-3 mRNA expression and activated caspase-3 protein 
levels were elevated following treatment with antimycin A. Although caspase-3 mRNA 
was significantly decreased following transfection in the antimycin A treated groups, the 
same was not found with regards to activated caspase-3 protein levels. There was a 
difference in the transfected groups from the scrambled siRNA group, but not from the 
positive control. Given the fact that procaspase-3 is present in normal cells, silencing may 
prevent more caspase-3 protein from being produced during IRI, but will not have an 
effect on that which has already been produced and can be activated. 
RelB silencing produced a benefit alone and in combination with caspase-3 silencing in 
terms of cell viability and apoptosis. There was a benefit seen when all three target genes 
were silenced as well. RelB is a transcription factor which is part of the NF-κβ signaling 
pathway and is responsible for the activation of many different genes. Attempting to 
silence part of this pathway could produce varying results as it can affect both survival 
and death. The mRNA expression of RelB was not significantly elevated when the cells 
were treated with antimycin A, however a benefit in terms of cell viability and reduced 
apoptosis was noted when RelB was silenced. 
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Complement 3 silencing did not produce a benefit in terms of reducing apoptosis or 
increasing the number of viable cells. Additionally, the mRNA expression of complement 
3 was significantly lower in the antimycin A treated cells. The RNA was only isolated 
following the recovery phase so it is possible that complement 3 is up-regulated later on 
in the process of IRI or only in the presence of other cell types. Complement 3 is at the 
convergence of all of the complement pathways and is constitutively produced by tubular 
epithelial cells. The complement system is known to be important in the propagation of 
cell injury following IRI and targeting this system was thought to useful in treating IRI 
(47, 88, 122). This project was limited to in vitro studies using tubular epithelial cells. 
The complement system requires many other cell types to function include leukocytes 
such as macrophages. The results which were obtained showing that complement 3 
silencing did not have any effect on cell death may be a result of this limitation. 
Complement 3 silencing in mouse models of IRI has been shown to be effective (52). It 
was still important to develop a porcine complement 3 siRNA that is effective at gene 
silencing and can be used in future ex vivo or in vivo experiments. 
Interestingly, there was no synergistic effect observed when multiple genes were 
silenced. This may have occurred for a number of reasons. First, the RISC complexes 
may have been completely saturated leading to competition between the sequences and a 
reduced silencing as some samples showed higher expression of mRNA when genes were 
targeted as opposed to a single gene. Second, IRI is a complex process and many 
different pathways are involved in cell damage and death and this redundancy may have 
lead to the results which were obtained. Third, only one cell type (tubular epithelial cells) 
was used in this study and this does not fully represent what occurs in an in vivo setting. 
The inflammatory response which is affected by RelB and complement 3 did not occur 
due to the lack of immune cells. 
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4.5 Conclusions 
In conclusion, caspase-3 and RelB siRNA were effective at gene silencing, increasing 
cell viability, and reducing apoptosis in an in vitro IRI model using antimycin A. 
Complement 3 siRNA was also tested, but did not show any significant difference in 
these outcomes. Interestingly, Complement 3 mRNA expression in this model was 
actually reduced. This project has also highlighted the need for large animal testing of 
therapies targeted at IRI and the limitations associated with in vitro and ischemia only 
models.  
4.6 Future Directions 
This project has lead to the development and confirmation of efficacy of porcine siRNA 
molecules. Future directions for this project involve the use of pigs as a large animal 
model to further study how RNA interference can be used effectively in the reduction of 
IRI. A DCD model will be used in which the kidneys will be subjected to warm ischemia 
prior to being perfused with preservation solutions. The delivery of siRNA molecules 
will be accomplished through the use of machine perfusion of isolated porcine kidneys. 
Optimal parameters for siRNA delivery will be determined and include temperature and 
perfusion pressure.  
This project will make use of an ischemia-only model of IRI in that the kidneys will not 
be reperfused with blood. Although this has some limitations, the process of IRI in the 
transplant setting has discrete ischemic and reperfusion phases. This allows for the 
opportunity to intervene in each of these phases and targeting events in the ischemic 
phase may be the most important in order to prevent subsequent events from occurring 
during the reperfusion phase. Preliminary results have been obtained with porcine 
kidneys which were procured after 1 hour of warm ischemia followed by either 24 or 42 
hours of perfusion at 37
0
C. Apoptosis was increased with increasing time on pump. 
These results are shown in Appendix B. The use of a large animal model is an important 
step in the translation to a clinical setting and will allow us to confirm our results which 
we have obtained from this in vitro model. 
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Appendix A: List of Abbreviations 
AKI Acute kidney injury 
ANOVA Analysis of variance 
C3 Complement 3 
DCD Donation after cardiac death 
ECD Expanded criteria donor 
miRNA Micro RNA 
NDD Neurologically determined death 
PCR Polymerase chain reaction 
piRNA PIWI-interacting RNA 
qPCR Quantitative real time polymerase chain reaction 
RNAi RNA interference 
RRT Renal replacement therapy 
SCD Standard criteria donor 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
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Appendix B – Preliminary Results from Pig Studies 
 
 
 
Figure 23 - TUNEL staining of porcine kidney tissue following 1h of warm ischemia 
and 0, 24, and 42h (as indicated) of perfusion at 37
0
C. Graphical representation 
showing percentage of cells staining positive for apoptosis. 
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Figure 24 - Quantitative Western Blot results showing expression of activated 
Caspase-3 in pig kidney tissue. n=1. 
As can be seen in Figures 23 and 24, apoptosis is increased in tissue obtained from pig 
kidneys which have undergone 1h of warm ischemia followed by perfusion at 37
0
C for 
24 and 42 hours. Activated caspase-3 is also increased in the tissue and supports the use 
of caspase-3 siRNA as a potential treatment for IRI in an ischemia only model. 
 
 
 
 
 
 
0 
0.5 
1 
1.5 
2 
2.5 
0h 24h 42h 
N
o
rm
al
iz
e
d
 t
o
 β
-a
ct
in
 
Western Blot 
Activated 
Caspase-3 
RelB 
97 
 
Appendix C - Copyright permission 
98 
 
99 
 
100 
 
101 
 
102 
 
103 
 
 
 
104 
 
Curriculum Vitae 
 
Name:   Terry Zwiep 
 
Post-secondary  Brock University 
Education and  St. Catharines, Ontario, Canada 
Degrees:   2004-2008 B.Sc. 
 
The University of Western Ontario 
London, Ontario, Canada 
2008-2012 MD 
 
Honours and   Ontario Graduate Scholarship 
Awards:   2014 
 
UWO Department of Surgery Resident Research Grant 
2014 
 
Related Work  General Surgery Resident 
Experience   Schulich School of Medicine and Dentistry 
The University of Western Ontario 
2012-present 
 
Publications: 
Tillman, B. W., Merritt, N. H., Emmerton-Coughlin, H., Mehrotra, S., Zwiep, T., & Lim, 
R. (2014). Acute gastric volvulus in a six-year-old: A case report and review of the 
literature. The Journal of Emergency Medicine, 46(2), 191. 
